OA18883A - Thiazolide compounds for treating viral infections - Google Patents
Thiazolide compounds for treating viral infections Download PDFInfo
- Publication number
- OA18883A OA18883A OA1201800372 OA18883A OA 18883 A OA18883 A OA 18883A OA 1201800372 OA1201800372 OA 1201800372 OA 18883 A OA18883 A OA 18883A
- Authority
- OA
- OAPI
- Prior art keywords
- virus
- hrv
- disease
- symptom
- condition
- Prior art date
Links
- OGYGFUAIIOPWQD-UHFFFAOYSA-N Thiazolidine Chemical class C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 title abstract description 9
- 208000001756 Virus Disease Diseases 0.000 title description 11
- 206010047461 Viral infection Diseases 0.000 title description 9
- 230000017613 viral reproduction Effects 0.000 title description 9
- YQNQNVDNTFHQSW-UHFFFAOYSA-N Nitazoxanide Chemical compound CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C([N+]([O-])=O)S1 YQNQNVDNTFHQSW-UHFFFAOYSA-N 0.000 claims abstract description 109
- 229960002480 nitazoxanide Drugs 0.000 claims abstract description 109
- 241000700605 Viruses Species 0.000 claims abstract description 106
- FDTZUTSGGSRHQF-UHFFFAOYSA-N Tizoxanide Chemical compound OC1=CC=CC=C1C(=O)NC1=NC=C([N+]([O-])=O)S1 FDTZUTSGGSRHQF-UHFFFAOYSA-N 0.000 claims abstract description 36
- 241000711504 Paramyxoviridae Species 0.000 claims abstract description 18
- 201000010099 disease Diseases 0.000 claims description 59
- 241000711408 Murine respirovirus Species 0.000 claims description 40
- 241000709661 Enterovirus Species 0.000 claims description 30
- 239000000203 mixture Substances 0.000 claims description 30
- 102000004169 proteins and genes Human genes 0.000 claims description 22
- 108090000623 proteins and genes Proteins 0.000 claims description 22
- 206010037660 Pyrexia Diseases 0.000 claims description 18
- 206010011224 Cough Diseases 0.000 claims description 16
- 241000893570 Hendra henipavirus Species 0.000 claims description 16
- 206010019233 Headache Diseases 0.000 claims description 13
- 206010068319 Oropharyngeal pain Diseases 0.000 claims description 13
- 231100000869 headache Toxicity 0.000 claims description 13
- 239000003443 antiviral agent Substances 0.000 claims description 12
- 208000000112 Myalgia Diseases 0.000 claims description 11
- 206010028748 Nasal obstruction Diseases 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 206010016256 Fatigue Diseases 0.000 claims description 10
- 230000000241 respiratory Effects 0.000 claims description 9
- 241000711920 Human orthopneumovirus Species 0.000 claims description 8
- 241000035314 Henipavirus Species 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 206010006448 Bronchiolitis Diseases 0.000 claims description 5
- 206010035664 Pneumonia Diseases 0.000 claims description 5
- 241000711902 Pneumovirus Species 0.000 claims description 5
- 206010013975 Dyspnoeas Diseases 0.000 claims description 4
- 230000035800 maturation Effects 0.000 claims description 4
- 206010061428 Decreased appetite Diseases 0.000 claims description 3
- 241001113283 Respirovirus Species 0.000 claims description 3
- 206010039083 Rhinitis Diseases 0.000 claims description 3
- 206010047924 Wheezing Diseases 0.000 claims description 3
- 230000004927 fusion Effects 0.000 claims description 3
- 229950007656 Rupintrivir Drugs 0.000 claims description 2
- CAYJBRBGZBCZKO-BHGBQCOSSA-N ethyl (E,4S)-4-[[(2R,5S)-2-[(4-fluorophenyl)methyl]-6-methyl-5-[(5-methyl-1,2-oxazole-3-carbonyl)amino]-4-oxoheptanoyl]amino]-5-[(3S)-2-oxopyrrolidin-3-yl]pent-2-enoate Chemical group C([C@@H](/C=C/C(=O)OCC)NC(=O)[C@@H](CC(=O)[C@@H](NC(=O)C1=NOC(C)=C1)C(C)C)CC=1C=CC(F)=CC=1)[C@@H]1CCNC1=O CAYJBRBGZBCZKO-BHGBQCOSSA-N 0.000 claims description 2
- 241000709664 Picornaviridae Species 0.000 abstract description 4
- 210000004027 cells Anatomy 0.000 description 106
- -1 thiazolide compound Chemical class 0.000 description 64
- 108060003023 F Proteins 0.000 description 23
- 230000002401 inhibitory effect Effects 0.000 description 20
- 239000011780 sodium chloride Substances 0.000 description 19
- 201000009910 diseases by infectious agent Diseases 0.000 description 18
- 150000001875 compounds Chemical class 0.000 description 17
- 150000003839 salts Chemical class 0.000 description 17
- 241000725643 Respiratory syncytial virus Species 0.000 description 16
- 230000003612 virological Effects 0.000 description 16
- ZHSGGJXRNHWHRS-VIDYELAYSA-N Tunicamycin Chemical compound O([C@H]1[C@@H]([C@H]([C@@H](O)[C@@H](CC(O)[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C(NC(=O)C=C2)=O)O)O1)O)NC(=O)/C=C/CC(C)C)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O ZHSGGJXRNHWHRS-VIDYELAYSA-N 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 239000003981 vehicle Substances 0.000 description 14
- VSZGPKBBMSAYNT-RRFJBIMHSA-N Oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 description 12
- 229960003752 Oseltamivir Drugs 0.000 description 12
- 230000000840 anti-viral Effects 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- 108090001123 antibodies Proteins 0.000 description 11
- 102000004965 antibodies Human genes 0.000 description 11
- 239000003112 inhibitor Substances 0.000 description 11
- 102000003886 Glycoproteins Human genes 0.000 description 9
- 108090000288 Glycoproteins Proteins 0.000 description 9
- 238000004166 bioassay Methods 0.000 description 9
- 239000002953 phosphate buffered saline Substances 0.000 description 9
- 238000001262 western blot Methods 0.000 description 9
- 229940068196 placebo Drugs 0.000 description 8
- 239000000902 placebo Substances 0.000 description 8
- 101710043164 Segment-4 Proteins 0.000 description 7
- 101700038759 VP1 Proteins 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000011248 coating agent Substances 0.000 description 7
- 101700005460 hemA Proteins 0.000 description 7
- 239000000185 hemagglutinin Substances 0.000 description 7
- 238000001243 protein synthesis Methods 0.000 description 7
- 230000014616 translation Effects 0.000 description 7
- 108009000409 Autophagy Proteins 0.000 description 6
- 210000000170 Cell Membrane Anatomy 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 6
- 108010067390 Viral Proteins Proteins 0.000 description 6
- 102000016350 Viral Proteins Human genes 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000006877 autophagy Effects 0.000 description 6
- 238000000376 autoradiography Methods 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 238000004448 titration Methods 0.000 description 6
- 241000991587 Enterovirus C Species 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 230000001154 acute Effects 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 125000001309 chloro group Chemical group Cl* 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 230000005892 protein maturation Effects 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 description 4
- GXJABQQUPOEUTA-RDJZCZTQSA-N Bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 4
- WHTVZRBIWZFKQO-UHFFFAOYSA-N Chloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 4
- 229960003677 Chloroquine Drugs 0.000 description 4
- 241000988556 Enterovirus B Species 0.000 description 4
- 208000009525 Myocarditis Diseases 0.000 description 4
- 210000004940 Nucleus Anatomy 0.000 description 4
- 229940032147 Starch Drugs 0.000 description 4
- 235000010443 alginic acid Nutrition 0.000 description 4
- 229920000615 alginic acid Polymers 0.000 description 4
- 230000004075 alteration Effects 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 229960001467 bortezomib Drugs 0.000 description 4
- 150000001649 bromium compounds Chemical class 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drugs Drugs 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 102000037240 fusion proteins Human genes 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 4
- 238000010166 immunofluorescence Methods 0.000 description 4
- 238000010820 immunofluorescence microscopy Methods 0.000 description 4
- 230000037041 intracellular level Effects 0.000 description 4
- 150000004694 iodide salts Chemical class 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 239000002609 media Substances 0.000 description 4
- 201000009906 meningitis Diseases 0.000 description 4
- 230000020978 protein processing Effects 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- LHEJDBBHZGISGW-UHFFFAOYSA-N 5-fluoro-3-(3-oxo-1H-2-benzofuran-1-yl)-1H-pyrimidine-2,4-dione Chemical compound O=C1C(F)=CNC(=O)N1C1C2=CC=CC=C2C(=O)O1 LHEJDBBHZGISGW-UHFFFAOYSA-N 0.000 description 3
- 101710027066 ALB Proteins 0.000 description 3
- 241000710189 Aphthovirus Species 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 229960005069 Calcium Drugs 0.000 description 3
- 241000710190 Cardiovirus Species 0.000 description 3
- 241001466953 Echovirus Species 0.000 description 3
- 241000988559 Enterovirus A Species 0.000 description 3
- 241000709715 Hepatovirus Species 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241000712003 Human respirovirus 3 Species 0.000 description 3
- 240000006600 Humulus lupulus Species 0.000 description 3
- 235000008694 Humulus lupulus Nutrition 0.000 description 3
- 238000010824 Kaplan-Meier survival analysis Methods 0.000 description 3
- 231100000002 MTT assay Toxicity 0.000 description 3
- 238000000134 MTT assay Methods 0.000 description 3
- 229920003091 Methocel™ Polymers 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N PMSF Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 description 3
- 206010057190 Respiratory tract infection Diseases 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 229940033134 Talc Drugs 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical class [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 201000010549 croup Diseases 0.000 description 3
- 230000001120 cytoprotect Effects 0.000 description 3
- 229940042399 direct acting antivirals Protease inhibitors Drugs 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000005755 formation reaction Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 239000001963 growth media Substances 0.000 description 3
- 230000002458 infectious Effects 0.000 description 3
- 239000002054 inoculum Substances 0.000 description 3
- SUMDYPCJJOFFON-UHFFFAOYSA-M isethionate Chemical compound OCCS([O-])(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-M 0.000 description 3
- 238000011068 load Methods 0.000 description 3
- 230000002934 lysing Effects 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 238000000386 microscopy Methods 0.000 description 3
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000004083 survival Effects 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- CIWBSHSKHKDKBQ-DUZGATOHSA-N (+)-Ascorbic acid Natural products OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 description 2
- VHJLVAABSRFDPM-UHFFFAOYSA-N 1,4-dimercaptobutane-2,3-diol Chemical compound SCC(O)C(O)CS VHJLVAABSRFDPM-UHFFFAOYSA-N 0.000 description 2
- VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-Chlorobutane Chemical class CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 2
- WMPPDTMATNBGJN-UHFFFAOYSA-N 2-Phenylethylbromide Chemical class BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl dihydrogen phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 2
- YJISHJVIRFPGGN-UHFFFAOYSA-N 5-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxy-6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)O)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 YJISHJVIRFPGGN-UHFFFAOYSA-N 0.000 description 2
- CWSZBVAUYPTXTG-UHFFFAOYSA-N 5-[6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxy-5-[4-hydroxy-3-(2-hydroxyethoxy)-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)OCCO)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 CWSZBVAUYPTXTG-UHFFFAOYSA-N 0.000 description 2
- 101700033661 ACTB Proteins 0.000 description 2
- 102100011550 ACTB Human genes 0.000 description 2
- 101710032514 ACTI Proteins 0.000 description 2
- XJKJWTWGDGIQRH-BFIDDRIFSA-N Alginic acid Chemical compound O1[C@@H](C(O)=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](C)[C@@H](O)[C@H]1O XJKJWTWGDGIQRH-BFIDDRIFSA-N 0.000 description 2
- 108050008484 Alpha tubulin Proteins 0.000 description 2
- 102000000132 Alpha tubulin Human genes 0.000 description 2
- 229940009098 Aspartate Drugs 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 229940050390 Benzoate Drugs 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L Calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- DSSYKIVIOFKYAU-UHFFFAOYSA-N Camphor Chemical compound C1CC2(C)C(=O)CC1C2(C)C DSSYKIVIOFKYAU-UHFFFAOYSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 241001668225 Cedar virus Species 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 206010008479 Chest pain Diseases 0.000 description 2
- 241000709687 Coxsackievirus Species 0.000 description 2
- 206010011416 Croup infectious Diseases 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N DATI Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- CKLJMWTZIZZHCS-UHFFFAOYSA-N DL-aspartic acid Chemical compound OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N Diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 241000991586 Enterovirus D Species 0.000 description 2
- 241001219115 Enterovirus H Species 0.000 description 2
- 241000033074 Enterovirus J Species 0.000 description 2
- 208000007212 Foot-and-Mouth Disease Diseases 0.000 description 2
- BJHIKXHVCXFQLS-UYFOZJQFSA-N Fructose Natural products OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 2
- 229960001031 Glucose Drugs 0.000 description 2
- 241001559187 Human rubulavirus 2 Species 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 210000004072 Lung Anatomy 0.000 description 2
- 210000004470 MDP Anatomy 0.000 description 2
- 241000351643 Metapneumovirus Species 0.000 description 2
- 208000005647 Mumps Diseases 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N N'-amino-N-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinylpyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- MQUQNUAYKLCRME-INIZCTEOSA-N N-tosyl-L-phenylalanyl chloromethyl ketone Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N[C@H](C(=O)CCl)CC1=CC=CC=C1 MQUQNUAYKLCRME-INIZCTEOSA-N 0.000 description 2
- 241000526636 Nipah henipavirus Species 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 208000008494 Pericarditis Diseases 0.000 description 2
- 208000000474 Poliomyelitis Diseases 0.000 description 2
- 239000007759 RPMI Media 1640 Substances 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 241001325464 Rhinovirus A Species 0.000 description 2
- 241001325459 Rhinovirus B Species 0.000 description 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N Rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 241000332040 Tupaia paramyxovirus Species 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 210000002845 Virion Anatomy 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 230000002730 additional Effects 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 229940077388 benzenesulfonate Drugs 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-M butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- MIOPJNTWMNEORI-UHFFFAOYSA-M camphorsulfonate anion Chemical compound C1CC2(CS([O-])(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-M 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-M caproate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 201000009230 common cold Diseases 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 2
- GAFRWLVTHPVQGK-UHFFFAOYSA-N dipentyl sulfate Chemical class CCCCCOS(=O)(=O)OCCCCC GAFRWLVTHPVQGK-UHFFFAOYSA-N 0.000 description 2
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N ethanolamine Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 201000006215 hand, foot and mouth disease Diseases 0.000 description 2
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxyl anion Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003834 intracellular Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-L maleate(2-) Chemical compound [O-]C(=O)\C=C/C([O-])=O VZCYOOQTPOCHFL-UPHRSURJSA-L 0.000 description 2
- 201000005505 measles Diseases 0.000 description 2
- 230000001404 mediated Effects 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000006011 modification reaction Methods 0.000 description 2
- 108010045030 monoclonal antibodies Proteins 0.000 description 2
- 102000005614 monoclonal antibodies Human genes 0.000 description 2
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- SJRJJKPEHAURKC-UHFFFAOYSA-N n-methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 2
- 201000009240 nasopharyngitis Diseases 0.000 description 2
- 230000002020 noncytotoxic Effects 0.000 description 2
- 231100000065 noncytotoxic Toxicity 0.000 description 2
- 230000003000 nontoxic Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-L oxalate Chemical compound [O-]C(=O)C([O-])=O MUBZPKHOEPUJKR-UHFFFAOYSA-L 0.000 description 2
- 230000001717 pathogenic Effects 0.000 description 2
- 244000052769 pathogens Species 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000002633 protecting Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 230000002829 reduced Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 239000002911 sialidase inhibitor Substances 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000001225 therapeutic Effects 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 2
- 229960001322 trypsin Drugs 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- ZDPHROOEEOARMN-UHFFFAOYSA-M undecanoate Chemical compound CCCCCCCCCCC([O-])=O ZDPHROOEEOARMN-UHFFFAOYSA-M 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N 1,2-ethanediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- VUQPJRPDRDVQMN-UHFFFAOYSA-N 1-chlorooctadecane Chemical class CCCCCCCCCCCCCCCCCCCl VUQPJRPDRDVQMN-UHFFFAOYSA-N 0.000 description 1
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 1
- LXFQSRIDYRFTJW-UHFFFAOYSA-M 2,4,6-trimethylbenzenesulfonate Chemical compound CC1=CC(C)=C(S([O-])(=O)=O)C(C)=C1 LXFQSRIDYRFTJW-UHFFFAOYSA-M 0.000 description 1
- WXTMDXOMEHJXQO-UHFFFAOYSA-M 2,5-dihydroxybenzoate Chemical compound OC1=CC=C(O)C(C([O-])=O)=C1 WXTMDXOMEHJXQO-UHFFFAOYSA-M 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-M 3-cyclopentylpropanoate Chemical compound [O-]C(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-M 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-M 5-oxo-L-prolinate Chemical compound [O-]C(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-M 0.000 description 1
- 102100017276 ADGRB3 Human genes 0.000 description 1
- 101710005063 ADGRB3 Proteins 0.000 description 1
- 102100001249 ALB Human genes 0.000 description 1
- 210000001015 Abdomen Anatomy 0.000 description 1
- 206010000059 Abdominal discomfort Diseases 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 241001247911 Aichivirus A Species 0.000 description 1
- 241001468000 Aichivirus B Species 0.000 description 1
- 241000986789 Aichivirus C Species 0.000 description 1
- 210000004712 Air Sacs Anatomy 0.000 description 1
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 241000272814 Anser sp. Species 0.000 description 1
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 1
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 1
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 1
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 1
- 241000031976 Aquamavirus Species 0.000 description 1
- 241000031975 Aquamavirus A Species 0.000 description 1
- 241000351313 Aquaparamyxovirus Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000711404 Avian avulavirus 1 Species 0.000 description 1
- 241001519465 Avian metapneumovirus Species 0.000 description 1
- 241001333905 Avian sapelovirus Species 0.000 description 1
- 241001651353 Avihepatovirus Species 0.000 description 1
- 241000035315 Avulavirus Species 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- PRDFBSVERLRRMY-UHFFFAOYSA-N Bisbenzimide Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 1
- 239000004135 Bone phosphate Substances 0.000 description 1
- 241000711895 Bovine orthopneumovirus Species 0.000 description 1
- 241001408568 Bovine rhinitis A virus Species 0.000 description 1
- 241001671987 Bovine rhinitis B virus Species 0.000 description 1
- 210000004556 Brain Anatomy 0.000 description 1
- 210000003123 Bronchioles Anatomy 0.000 description 1
- 206010006451 Bronchitis Diseases 0.000 description 1
- 241000031977 Cadicivirus A Species 0.000 description 1
- 229960003563 Calcium Carbonate Drugs 0.000 description 1
- 229940078495 Calcium phosphate dibasic Drugs 0.000 description 1
- JHLNERQLKQQLRZ-UHFFFAOYSA-N Calcium silicate Chemical compound [Ca+2].[Ca+2].[O-][Si]([O-])([O-])[O-] JHLNERQLKQQLRZ-UHFFFAOYSA-N 0.000 description 1
- 241000712083 Canine morbillivirus Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate dianion Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241001632249 Cosavirus Species 0.000 description 1
- 241000146296 Coxsackievirus A12 Species 0.000 description 1
- 241000146307 Coxsackievirus A13 Species 0.000 description 1
- 241000146306 Coxsackievirus A14 Species 0.000 description 1
- 241001429382 Coxsackievirus A16 Species 0.000 description 1
- 241000146309 Coxsackievirus A17 Species 0.000 description 1
- 241000146305 Coxsackievirus A19 Species 0.000 description 1
- 241001466951 Coxsackievirus A2 Species 0.000 description 1
- 241000146316 Coxsackievirus A20 Species 0.000 description 1
- 241000709698 Coxsackievirus A21 Species 0.000 description 1
- 241000709734 Coxsackievirus A24 Species 0.000 description 1
- 241000146325 Coxsackievirus A3 Species 0.000 description 1
- 241000146328 Coxsackievirus A4 Species 0.000 description 1
- 241000146327 Coxsackievirus A5 Species 0.000 description 1
- 241001669084 Coxsackievirus A6 Species 0.000 description 1
- 241000146321 Coxsackievirus A7 Species 0.000 description 1
- 241000146319 Coxsackievirus A8 Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 229960000913 Crospovidone Drugs 0.000 description 1
- 229940026599 Cryptosporidium parvum Drugs 0.000 description 1
- 241000223936 Cryptosporidium parvum Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 208000000264 Deglutition Disorders Diseases 0.000 description 1
- 229940096516 Dextrates Drugs 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000031978 Dicipivirus Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 206010013950 Dysphagia Diseases 0.000 description 1
- 206010013952 Dysphonia Diseases 0.000 description 1
- 229940022766 EGTA Drugs 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000033147 ERVK-25 Human genes 0.000 description 1
- 241000710188 Encephalomyocarditis virus Species 0.000 description 1
- 241001529459 Enterovirus A71 Species 0.000 description 1
- 241000950667 Enterovirus A76 Species 0.000 description 1
- 241000950654 Enterovirus A89 Species 0.000 description 1
- 241001193654 Enterovirus A90 Species 0.000 description 1
- 241000950655 Enterovirus A91 Species 0.000 description 1
- 241000791999 Enterovirus B106 Species 0.000 description 1
- 241000693328 Enterovirus B69 Species 0.000 description 1
- 241001143392 Enterovirus B73 Species 0.000 description 1
- 241000253979 Enterovirus B74 Species 0.000 description 1
- 241000784768 Enterovirus B75 Species 0.000 description 1
- 241000253975 Enterovirus B77 Species 0.000 description 1
- 241001329704 Enterovirus B80 Species 0.000 description 1
- 241001329702 Enterovirus B82 Species 0.000 description 1
- 241001329746 Enterovirus B87 Species 0.000 description 1
- 241000768495 Enterovirus B93 Species 0.000 description 1
- 241001665992 Enterovirus B97 Species 0.000 description 1
- 241001588231 Enterovirus B98 Species 0.000 description 1
- 241000919800 Enterovirus C95 Species 0.000 description 1
- 241001665994 Enterovirus C96 Species 0.000 description 1
- 241000919795 Enterovirus C99 Species 0.000 description 1
- 241000709691 Enterovirus E Species 0.000 description 1
- 241000033076 Enterovirus F Species 0.000 description 1
- 241001523584 Enterovirus G Species 0.000 description 1
- 206010014978 Epidemic pleurodynia Diseases 0.000 description 1
- 241000214054 Equine rhinitis A virus Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241001468007 Erbovirus Species 0.000 description 1
- 241001239777 Erbovirus A Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010016165 Failure to thrive Diseases 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000521069 Ferlavirus Species 0.000 description 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229960002737 Fructose Drugs 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N Glycerol 3-phosphate Chemical compound OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N Glyceryl behenate Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 208000006572 Human Influenza Diseases 0.000 description 1
- 241000158857 Human enterovirus C104 Species 0.000 description 1
- 241000342334 Human metapneumovirus Species 0.000 description 1
- 241001214603 Human rhinovirus A1 Species 0.000 description 1
- 241001326003 Human rhinovirus A18 Species 0.000 description 1
- 241001098647 Human rhinovirus A19 Species 0.000 description 1
- 241001098652 Human rhinovirus A24 Species 0.000 description 1
- 241001326007 Human rhinovirus A28 Species 0.000 description 1
- 241001099058 Human rhinovirus A34 Species 0.000 description 1
- 241001099055 Human rhinovirus A39 Species 0.000 description 1
- 241001099031 Human rhinovirus A47 Species 0.000 description 1
- 241000178584 Human rhinovirus A49 Species 0.000 description 1
- 241001099008 Human rhinovirus A51 Species 0.000 description 1
- 241001099015 Human rhinovirus A57 Species 0.000 description 1
- 241000178582 Human rhinovirus A58 Species 0.000 description 1
- 241001099102 Human rhinovirus A61 Species 0.000 description 1
- 241001099100 Human rhinovirus A63 Species 0.000 description 1
- 241000178580 Human rhinovirus A65 Species 0.000 description 1
- 241001099095 Human rhinovirus A66 Species 0.000 description 1
- 241001099098 Human rhinovirus A71 Species 0.000 description 1
- 241001325983 Human rhinovirus A78 Species 0.000 description 1
- 241001099083 Human rhinovirus A85 Species 0.000 description 1
- 241001099087 Human rhinovirus A88 Species 0.000 description 1
- 241000710120 Human rhinovirus A89 Species 0.000 description 1
- 241001098665 Human rhinovirus B4 Species 0.000 description 1
- 241000414017 Human rhinovirus B84 Species 0.000 description 1
- 241000798964 Human rhinovirus C12 Species 0.000 description 1
- 241000798924 Human rhinovirus C15 Species 0.000 description 1
- 241001357309 Human rhinovirus C17 Species 0.000 description 1
- 241000798965 Human rhinovirus C18 Species 0.000 description 1
- 241000798966 Human rhinovirus C20 Species 0.000 description 1
- 241000798991 Human rhinovirus C22 Species 0.000 description 1
- 241000798962 Human rhinovirus C25 Species 0.000 description 1
- 241000798946 Human rhinovirus C28 Species 0.000 description 1
- 241001354547 Human rhinovirus C3 Species 0.000 description 1
- 241000798948 Human rhinovirus C36 Species 0.000 description 1
- 241000798961 Human rhinovirus C37 Species 0.000 description 1
- 241000798922 Human rhinovirus C39 Species 0.000 description 1
- 241000798963 Human rhinovirus C49 Species 0.000 description 1
- 241000798926 Human rhinovirus C5 Species 0.000 description 1
- 241001354548 Human rhinovirus C6 Species 0.000 description 1
- 241001559186 Human rubulavirus 4 Species 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 210000000987 Immune System Anatomy 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 206010022000 Influenza Diseases 0.000 description 1
- 206010022004 Influenza like illness Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 210000000936 Intestines Anatomy 0.000 description 1
- 210000003734 Kidney Anatomy 0.000 description 1
- 241001468006 Kobuvirus Species 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
- 101700009300 LCM Proteins 0.000 description 1
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 1
- 229960001375 Lactose Drugs 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- HBBGRARXTFLTSG-UHFFFAOYSA-N Lithium Ion Chemical compound [Li+] HBBGRARXTFLTSG-UHFFFAOYSA-N 0.000 description 1
- 241000708386 Ljungan virus Species 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 206010025482 Malaise Diseases 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N Maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N Meglumine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 241000031979 Megrivirus Species 0.000 description 1
- 241000031981 Melegrivirus A Species 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 241000712045 Morbillivirus Species 0.000 description 1
- 210000000214 Mouth Anatomy 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 241000711941 Murine orthopneumovirus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028323 Muscle pain Diseases 0.000 description 1
- GIFKVQOPAJDJLO-YQHXDJBWSA-N N'-anilino-N-[(4,5-dimethyl-1,3-thiazol-2-yl)imino]benzenecarboximidamide Chemical compound S1C(C)=C(C)N=C1N=N\C(C=1C=CC=CC=1)=N/NC1=CC=CC=C1 GIFKVQOPAJDJLO-YQHXDJBWSA-N 0.000 description 1
- JQUDKSXFZCWBTC-UHFFFAOYSA-N N-(5-chloro-1,3-thiazol-2-yl)-2-hydroxybenzamide Chemical compound OC1=CC=CC=C1C(=O)NC1=NC=C(Cl)S1 JQUDKSXFZCWBTC-UHFFFAOYSA-N 0.000 description 1
- QIAFMBKCNZACKA-UHFFFAOYSA-M N-benzoylglycinate Chemical compound [O-]C(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-M 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N N-benzyl-1-phenylmethanamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- FRCFWPVMFJMNDP-UHFFFAOYSA-N N-propan-2-ylaniline Chemical compound CC(C)NC1=CC=CC=C1 FRCFWPVMFJMNDP-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 210000001331 Nose Anatomy 0.000 description 1
- 229940096978 Oral Tablet Drugs 0.000 description 1
- 241001137886 Ovine respiratory syncytial virus Species 0.000 description 1
- XAPRFLSJBSXESP-UHFFFAOYSA-N Oxycinchophen Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=C(O)C=1C1=CC=CC=C1 XAPRFLSJBSXESP-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N Pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 241000711502 Paramyxovirinae Species 0.000 description 1
- 241000873939 Parechovirus A Species 0.000 description 1
- 108091005771 Peptidases Proteins 0.000 description 1
- 229940072417 Peroxidase Drugs 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 108090000437 Peroxidases Proteins 0.000 description 1
- 210000003800 Pharynx Anatomy 0.000 description 1
- 241000711899 Phocine morbillivirus Species 0.000 description 1
- 241000295697 Pimephales promelas Species 0.000 description 1
- 229950010765 Pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N Pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 206010035623 Pleuritic pain Diseases 0.000 description 1
- 241000711904 Pneumoviridae Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001451 Polypropylene glycol Polymers 0.000 description 1
- RKCAIXNGYQCCAL-UHFFFAOYSA-N Porphin Chemical compound N1C(C=C2N=C(C=C3NC(=C4)C=C3)C=C2)=CC=C1C=C1C=CC4=N1 RKCAIXNGYQCCAL-UHFFFAOYSA-N 0.000 description 1
- 229960003975 Potassium Drugs 0.000 description 1
- 241000048284 Potato virus P Species 0.000 description 1
- 229940069328 Povidone Drugs 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N Procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940043131 Pyroglutamate Drugs 0.000 description 1
- 206010037844 Rash Diseases 0.000 description 1
- 206010037898 Rash vesicular Diseases 0.000 description 1
- 241000531454 Reptilian ferlavirus Species 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 241001139982 Rhinovirus C Species 0.000 description 1
- 241000711897 Rinderpest morbillivirus Species 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 241001533467 Rubulavirus Species 0.000 description 1
- 241001352312 Salivirus Species 0.000 description 1
- 241000033084 Salivirus A Species 0.000 description 1
- 241000481302 Salmon aquaparamyxovirus Species 0.000 description 1
- 241001333897 Sapelovirus Species 0.000 description 1
- 241001333903 Sapelovirus A Species 0.000 description 1
- 241001333901 Sapelovirus B Species 0.000 description 1
- 241000837158 Senecavirus A Species 0.000 description 1
- 241001428894 Small ruminant morbillivirus Species 0.000 description 1
- 206010041232 Sneezing Diseases 0.000 description 1
- 210000000278 Spinal Cord Anatomy 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 206010042241 Stridor Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 1
- 229960004793 Sucrose Drugs 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L Sulphite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 241000249096 Teschovirus Species 0.000 description 1
- 241000249107 Teschovirus A Species 0.000 description 1
- CBXCPBUEXACCNR-UHFFFAOYSA-N Tetraethylammonium Chemical compound CC[N+](CC)(CC)CC CBXCPBUEXACCNR-UHFFFAOYSA-N 0.000 description 1
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 1
- 210000003437 Trachea Anatomy 0.000 description 1
- 229940116362 Tragacanth Drugs 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 241001365589 Tremovirus Species 0.000 description 1
- 241001223089 Tremovirus A Species 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229940066528 Trichloroacetate Drugs 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N Trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
- FPKOPBFLPLFWAD-UHFFFAOYSA-N Trinitrotoluene Chemical compound CC1=CC=C([N+]([O-])=O)C([N+]([O-])=O)=C1[N+]([O-])=O FPKOPBFLPLFWAD-UHFFFAOYSA-N 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K Tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 230000036462 Unbound Effects 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 229940100445 WHEAT STARCH Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N Xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 Xylitol Drugs 0.000 description 1
- 208000003558 Zoonosis Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000240 adjuvant Effects 0.000 description 1
- 229940050528 albumin Drugs 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000111 anti-oxidant Effects 0.000 description 1
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 230000003115 biocidal Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 201000009030 carcinoma Diseases 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 239000011247 coating layer Substances 0.000 description 1
- 230000023298 conjugation with cellular fusion Effects 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 230000000120 cytopathologic Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 150000008050 dialkyl sulfates Chemical class 0.000 description 1
- 201000008286 diarrhea Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- ROSDSFDQCJNGOL-UHFFFAOYSA-N dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-M dodecyl sulfate Chemical compound CCCCCCCCCCCCOS([O-])(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-M 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N ethyl amine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 230000002496 gastric Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940114119 gentisate Drugs 0.000 description 1
- 201000006592 giardiasis Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-L glutarate(2-) Chemical compound [O-]C(=O)CCCC([O-])=O JFCQEDHGNNZCLN-UHFFFAOYSA-L 0.000 description 1
- 229940049654 glyceryl behenate Drugs 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 230000003899 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003067 hemagglutinative Effects 0.000 description 1
- 201000006219 herpangina Diseases 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- BICAGYDGRXJYGD-UHFFFAOYSA-N hydrobromide;hydrochloride Chemical compound Cl.Br BICAGYDGRXJYGD-UHFFFAOYSA-N 0.000 description 1
- 125000004435 hydrogen atoms Chemical class [H]* 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 229940079866 intestinal antibiotics Drugs 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M isothiocyanate Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000001466 metabolic labeling Methods 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M methanoate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000000329 molecular dynamics simulation Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 229960000060 monoclonal antibodies Drugs 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N nicotinic acid Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 230000000474 nursing Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000001314 paroxysmal Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NJRWNWYFPOFDFN-UHFFFAOYSA-L phosphonate(2-) Chemical compound [O-][P]([O-])=O NJRWNWYFPOFDFN-UHFFFAOYSA-L 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 108091008117 polyclonal antibodies Proteins 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
- 230000002335 preservative Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrugs Drugs 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L propanedioate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 230000004845 protein aggregation Effects 0.000 description 1
- 150000003217 pyrazoles Chemical class 0.000 description 1
- 230000001850 reproductive Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N silicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained Effects 0.000 description 1
- 230000002522 swelling Effects 0.000 description 1
- 230000005700 syncytium formation by plasma membrane fusion Effects 0.000 description 1
- 201000010874 syndrome Diseases 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 239000006068 taste-masking agent Substances 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 210000001519 tissues Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 230000014599 transmission of virus Effects 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-M trichloroacetate Chemical compound [O-]C(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-M 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 229960005486 vaccines Drugs 0.000 description 1
- 244000052613 viral pathogens Species 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- DHCLVCXQIBBOPH-UHFFFAOYSA-N β-glycerophosphoric acid Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 1
Abstract
Thiazolide compounds, such as nitazoxanide and/or tizoxanide, may be used against viruses belonging to the Picornaviridae family or the Paramyxoviridae family.
Description
Romark Laboratories L.C.
Thiazolide compounds for treating viral infections
PRIORITY
The présent application daims priority to U.S. provisional application no. 62/316,463 filed March 31, 2016, which is incorporated herein in its entirety.
FIELD
The présent application generally relates to thiazolide compounds and more particularly, to their use in treatment of certain virai infections.
SUMMARY
A method of treating a disease or condition caused by or associated with a virus belonging to the Paramyxoviridae family, comprises admînistering to a subject in need thereof an effective amount of a pharmaceutical composition comprising at least one of nitazoxanide or tizoxanide or a pharmaceutically acceptable sait thereof, wherein the effective amount is an amount which blocks in the subject the maturation of the F glycoprotein of the virusi
A method of treating a disease or condition caused by or associated with a virus belonging to the Picontaviridae family, comprises admînistering to a subject in need thereof a therapeutically effective amount ofa pharmaceutical composition comprising at least one of nitazoxanide or tizoxanide or a pharmaceutically acceptable sait thereof.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. I is a Kaplan-Meier survival analysis chart for respiratory syncytial virus (RSV) infected patients treated with nitazoxanide and placebo. TTSALL stands for Time to Symptom Alleviation (hours). This plot shows that treatment with nitazoxanide was associated with a 76 hour réduction in duration of symptoms at the médian.
FIG. 2 is a Kaplan-Meier survival chart for patients infected with a virus belonging to the Enterovirus genus (including enteroviruses and rhinoviruses) identified as their sole cause of illness and treated with a) nitazoxanide; b) nitazoxanide and oseltamivir; c) oseltamivir and d) placebo.
-118883
FIG. 3 is a Kaplan-Meier survival chart for patients infected with a virus belonging to the Enterovirus genus (including enteroviruses and rhinoviruses) identified as their sole cause of illness and treated with a) nitazoxanideperse or a combination of nitazoxanide and oseltamivir and b) oseltamîvirper se or placebo.
FIG. 4A-B illustrate antiviral activity of nitazoxanide in Sendai virus infected AGMK cells. In particular, FIG 4A présents a plot showing inhibition of Sendai virus as a fonction nitazoxanide concentration. FIG 4B présents photographs of control, untreated Sendai virus and Sendai virus treated with nitazoxanide.
FIG. 5 présents inhibition plots for Sendai virus (SeV) as a fonction of nitazoxanide concentration for different multiplicities of infection and different type of cells. The data in FIG. 5 show that antiviral activity of nitazoxanide in SeV-infected cells is independent of the multiplicity of infection and the cell type.
FIG. 6 présents SDS-PAGE data demonstrating effect of nitazoxanide on SeV protein synthesis.
FIG. 7 présents SDS-PAGE and Western Blot data demonstrating effect of Nitazoxanide on SeV-F protein synthesis.
FIG. 8 présents Western Blot data demonstrating détection of the immature form of SeV-F protein in the insoluble fraction of nitazoxanide (NTZ) treated AGMK protein extracts.
FIG. 9 présents Western Blot data demonstrating détection of the immature form of SeV-F protein in the insoluble fraction of nitazoxanide (NTZ) treated AGMK protein extracts.
FIG. 10 présents photographs, which provide evidence that nitazoxanide inhibits transport of Hendra virus (HeV) F glycoprotein to the cell surface.
FIG. 11A-C illustrate inhibition of SeV parainfluenza virus by nitazoxanide in AGMK cells. A,B. NTZ inhibits SeV réplication under single-step (A) and multistep (B) virus growth conditions. Monkey kidney AGMK cells infected with SeV were treated with different concentrations of NTZ or vehicle immediately after the virus adsorption period. Virus yield (O) was determined at 24 (A) or 48 (B) h post infection (p.i.) by hemagglutinin titration (right panels) and plaque assay (left panels). Virus yield, expressed in HA units (HAU)/ml or
-218883
PFU/ml, represents the mean±SD of quadruplîcate samples. *=p<0.05; **=p<0.0l. Cell viability of mock-infected cells (Δ) was determined by MTT assay. (C) Cytoprotective effect of NTZ (10 pg/ml) in SeV-înfected AGMK cells at 24 h p.i..
NTZ was effective in inhibiting SeV réplication at concentrations that were non-toxîc for the host cells. NTZ was actually cytoprotective in infected cells. In fact SeV infection (3 PFU/cell) is generally characterized by a massive cytopathîc effect, causing a change in cell shape and size, and loss of adhesion (Panel C, SeV). NTZ treatment (10 pg/ml), in addition to inhibiting virus progeny production, was also found to protect AGMK cells from virusinduced damage (Panel C, SeV + NTZ ). The information in FIG. 11A-C is similar to the information in FIG. 4A-B.
FIG. 12 présents data demonstrating inhibition of SeV paraînfluenza virus by nitazoxanide in human alveolar A549 cells. Human alveolar type II-like A549 cells infected with SeV under single-step (3 PFU/cell) and multistep (0.01 PFU/cell) virus growth conditions were treated with different concentrations of NTZ or vehicle immediately after the virus adsorption period. Virus yield (O) was determined at 24 (single-step) or 48 (multistep) h p.i. by HA titration. Virus yield, expressed as percent of untreated control, represents the mean±SD of quadruplîcate samples. *=p<0.05; **=p<0.0l.
NTZ antiviral activity was independent of the cell type. NTZ was in fact also effective in human alveolar type II-like A549 cells infected with SeV. The data in Figure 12 are similar to the data in Figure 5.
FIG. 13 A-B show the effect of Nitazoxanide on SeV protein synthesis.
(A) Autoradiography of [35S]Met/Cys-labeled proteins (long-pulse, 18 h started at 6 h p.i.) from mock-infected (Mock) or SeV-infected (SeV) AGMK cells treated with 10 pg/ml NTZ,
2.5 gg/ml tunicamycin (TM) or vehicle (C) after virus adsorption. Viral proteins are indicated.
(B) Autoradiography of [3îS]Met/Cys-labeled proteins (short-pulse, l h) at 24 h p.i. from mock-infected or SeV-infected cells treated as in (A). Samples containing equal amounts of radioactivity (right panel, cpm) or equal amounts of proteins (left panel, ml) were processed for SDS-PAGE and autoradiography.
-318883
The main SeV proteins were found to be synthesized in large amounts in untreated cells at 24 h p.i. after both long (A, 18 h) and short (B, l h) [35S]Met/Cys-labeling puises; no major changes in SeV protein synthesis were detected in NTZ-treated cells, with the exception of the disappearance of a band of approximately 65-70 kDa molecular mass, subsequently identified as the mature isoform of the fusion protein precursor Fo (see Fig. 14). The data in FIG. 13AB are similar to data in FIG. 7.
FIG. 14A-B show the effect of Nitazoxanide on SeV Fusion protein.
(A) Levels of SeV-F protein were detected by Western blot analysis using a monoclonal SeVF antibody at different times p.i. in SeV-infected AGMK cells treated with 10 pg/ml NTZ, 2.5 pg/ml tunicamycin (TM ) or vehicle (C). Mock-infected (Mock) control is shown. Levels of α-tubulin in the same samples are shown as loading control. (B) Autoradiography of [35S]Met/Cys-labeled proteins (l h-pulse at different times p.i.) from mock-infected (Mock) or SeV-infected AGMK cells treated with 10 pg/ml NTZ or vehicle (C) after virus adsorption. Viral NP and F proteins are indicated.
The results confirm the absence of the SeV Fusion protein in NTZ-treated cells. Similar results were shown in TM-treated cells. The data in FIG. 14A-B are similar to data in FIG. 8.
FIG. I5A-B show that nitazoxanide causes SeV-F protein insolubilization.
Western blot analysis for SeV-F and β-actin in mock-infected or SeV-infected AGMK cells treated with 10 pg/ml NTZ, 2.5 pg/ml tunicamycin (TM ) or vehicle (C) in the presence (+) or the absence (-) of the protéasome inhibitor bortezomib (Btz, 25 nM), or the autophagy inhibitor chloroquine (CQ, 20 or 40 μΜ). (A). Soluble fractions of cell lysâtes extracted with Buffer-B (Soluble) or total cell lysâtes from parallel samples extracted with Laemmli sample Buffer (Total) are indicated. (B) Immunoblot for SeV-F and β-actin of Soluble and Insoluble fractions of whole-cell extracts extracted with Buffer-B from AGMK cells treated as indicated. Insoluble fractions were processed as described in Materials and Methods. Fp indicates the faster-migrating F form in NTZ-treated cells.
F protein level réduction in NTZ-treated cells was not prevented by the protéasome inhibitor bortezomib or by the autophagy inhibitor chloroquine, indicating an effect independent of
-418883 protéasome- or autophagy-mediated dégradation; instead the F-protein was found in an insoluble State in NTZ-treated cells, indicating that an alteration in protein processing/maturation could lead to the formation of F-protein aggregates présent in an insoluble State. The data in FIG. 15A-B are similar to data in FIG. 9.
FIG. 16 provides evidence of the presence of large SeV-F protein aggregates in nitazoxanidetreated cells.
Immunoconfocal-microscopy of mock-infected (Mock) and SeV-infected AGMK cells treated with NTZ (10 pg/ml) or vehicle for 24 h, labeled with anti-calnexin (CNX, green) and antiSeV-F (red) antîbodies. Nuclei are stained with DAPI (bine). Images were captured with Olympus Fluoview FV-1000 confocal laser scanning System. The overlay of the three fluorochromes (MER.GE) and Zoom images are shown (bar, 7 pm).
Immunoconfocal-microscopy studies confirm the presence of large F-protein aggregates in the ER of NTZ-treated cells.
FIG. 17 shows that nitazoxanide inhibits SeV-F glycoprotein transport to the cell surface.
Levels of SeV-F plasma-membrane glycoproteins (red) were detected at 24 h p.i. by confocal immunofluorescence microscopy in SeV-infected AGMK cells treated with 10 pg/ml NTZ or vehicle (SeV). Mock-infected (Mock) cells are shown as control. Nuclei are stained with Hoechst (bine). Images were captured with Olympus Fluoview FV-1000 confocal laser scanning system. The overlay of the two fluorochromes is shown (bar =10 pm).
The presence of the F-protein could not be detected on the host cell surface of NTZ-treated cells, confirming that the alteration in the F protein processing/maturation prevents its transport to the cell membrane.
FIG. 18A-B show that nitazoxanide causes Hendra virus (HeV) and Respiratory Syncytial virus (RSV) F protein insolubilization.
A. Western blot analysis for HeV-F and α-tubulîn of HeLa cells mock-transfected or transfected with the HeV-F ORF C-Flag tag construct expressing the HeV-F protein, as described in Materials and Methods, and treated with 5 pg/ml NTZ (C+), 2.5 pg/ml tunicamycin (TM) or vehicle (C-). B. Western blot analysis for RSV-F and α-tubulin of HeLa -518883 cells mock-transfected or transfected with the RSV-F ORF C-Flag tag construct expressing the RSV-F protein, as described in Materials and Methods, and treated with 5 pg/ml NTZ (C+), 2.5 pg/ml tunicamycin (TM) or vehicle (C-). A,B. Soluble fractions of cell lysâtes extracted with Buffer-B (Soluble) or total cell lysâtes from parallel samples extracted with Laemmli sample Buffer (Total), as described in Materials and Methods, are indicated. HeV-F and RSV-F proteins were detected using anti-FLAG antibodies. Fp indicates the fastermigrating F form in TM-treated cells.
HeV and RSV F-protein was mostly detected in an insoluble state in NTZ-treated cells, îndicating that, similarly to the SeV F protein, an alteration in protein processing/maturation could lead to the formation of F-protein aggregates présent in an insoluble state.
FIG. 19A-B show that nitazoxanide inhibits HeV-F and RSV-F glycoprotein transport to the cell surface.
A. Levels of HeV-F plasma-membrane glycoproteins (red) were detected at 24 h p.i. by confocal immunofluorescence microscopy in non-permeabilized HeLa cells mock-transfected or transfected with the HeV-F ORF C-Flag tag construct expressing the HeV-F protein, as described in Materials and Methods, and treated with 5 pg/ml NTZ or vehicle. B. Levels of RSV-F plasma-membrane glycoproteins (red) were detected at 24 h p.i. by confocal immunofluorescence microscopy in non-permeabilized HeLa cells mock-transfected or transfected with the RSV-F ORF C-Flag tag construct expressing the RSV-F protein, as described in Materials and Methods, and treated with 5 pg/ml NTZ or vehicle. A,B. F proteins were detected using anti-FLAG antibodies (red). Nuclei are stained with Hoechst (bine). Mock-transfected (Mock) cells are shown as control. Images were captured with Olympus Fluoview FV-1000 confocal laser scanning System. The overlay of the two fluorochromes is shown.
The presence of the F-protein was detected at a lower level on the host cell surface of NTZtreated cells indicating that, similarly to the SeV F protein, the alteration in the HeV and RSV F protein processing/maturation prevents its transport to the cell membrane.
In the case of RSV infection, nitazoxanide was found to possess antiviral activity against RSV-A2 in HeLa cells at non cytotoxic doses, with an ICs0 of 0.3 pg/ml and an IC90 of 0.8
-618883 gg/ml (for details of RSV infection see Materials and Methods). The data in FIG. 19A-B are similar to data in FIG. 10.
DETAILED DESCRIPTION
Related documents
The following documents, which are ail incorporated by reference, may be usefiil for understanding the présent disclosure: U.S. patents nos. 9,351,937; 9,126,992; 9,107,913; 9,023,877; 8,895,752; 8,846,727; 8,772,502; 8,633,230; 8,524,278;8,124,632; 7,645,783; 7,550,493; 7,285,567; 6,117,894; 6,020,353; 5,968,961; 5,965,590; 5,935,591; 5,886,013; 5,859,038; 5,856,348; 5,387,598; U.S. patent application publications nos. 2015-025768; 2014-0065215; 2012-0294831; 2016-0243087; PCT publication no. WO2016077420; J. Biol. Chem., 2009 Oct 23; 284(43): 29798-29808; Antiviral Research, 110(2014): 94-103; Biochim Biophys Acta., 2003 Jul 11; 1614( 1):73-84.
Définition of terms
Unless otherwise specifïed, “a” or “an” means “one or more.”
As used herein, the term “viral infection” describes a diseased State, in which a virus invades a healthy cell, uses the cell’s reproductive machinery to multiply or replicate and ultimately lyse the cell resulting in cell death, release of viral particles and the infection of other cells by the newly produced progeny viruses. Latent infection by certain viruses is also a possible resuit of viral infection. An acute virus infection is usually characterized by a rapid onset of a disease, a relatively brief period of symptoms, and resolution within days to a few weeks. It is usually accompanied by early production of infectious virions and élimination of infection by the host immune system. Acute viral infections are responsible for épidémies of disease involving millions of individuals each year. When vaccines are not available or not used, acute infections can be difficult to control since an infected individual is usually infectious prior to becoming ill. This makes it exceedingly difficult to control acute infections in large populations and densely populated areas such as colleges, nursing homes, mîlitary bases or ships. Children, the elderly and immunocompromised individuals are more susceptible to complications from these normally self-limiting infections.
-Ί18883
The tenu “a disease or condition caused by or associated with a virus” may refer to a viral infection caused by the virus and/or one or more of its symptoms, which may be associated with the viral infection.
As used herein, the terni “treating and/or preventing a disease or condition caused by or associated with a virus” may include at least one of the following: înhibiting the réplication of the virus, înhibiting viral transmission, preventing the virus from establishing itself in its host, ameliorating or alleviating the symptoms or progression of the disease caused by the virus. The treatment is considered therapeutic if there is at least one of a réduction in viral load, decrease in mortaiity and/or morbidity related with the disease, decrease in the progression of the disease or a shorter duration of the disease. In certain embodiments, “treating and/or preventing a disease or condition caused by or associated with a virus” may include increased survival among subjects affected with the disease or condition caused by or associated with influença virus and treated with an active agent, such as a thiazolide compound, compared to subjects affected with the disease or condition but not treated with the active agent. In certain embodiments, ‘Treating and/or preventing a disease or condition caused by or associated with a virus” may include réduction of a viral load in a subject affected with the disease or condition caused by or associated with the virus upon administering an active agent. Yet in sonie embodiments, “treating and/or preventing a disease or condition caused by or associated with a virus” may include ameliorating or alleviating the symptoms or progression of the disease caused by the virus.
Disclosure
The présent inventors discovered that certain thiazolide compounds may be effective against viruses belonging to the Picomaviridae and Paramyxoviridae viral families.
In particular, such compounds may be useful for treating or preventing a disease or condition caused by or associated with a virus belonging to the Picomaviridae and Paramyxoviridae viral families.
PICORNAVIRIDAE VIRAL FAMILY
The Piconiaviridae family is a (+)ssRNA viral family. Vertebrates, including humans, may serve as naturel hosts for picomaviruses. There are currently 50 species in this family, divided -818883 among 29 généra. The généra of the Picomaviridae family include: Aphthovirus genus, which includes Bovine rhinitis A virus, Bovine rhinitis B virus, Equine rhinitis A virus, Footand-mouth disease virus; Aquamavirus genus, which includes Aquamavirus A;
Avihepatovirus genus, which includes Duck hepatîtis A virus; Cardiovirus genus, which includes Encephalomyocarditis virus, thilovirus, Cosavirus; Dicipivirus genus, which includes cadicivirus A; Enterovirus genus, which includes enteroviruses A-J and rhinoviruses A-C; Erbovirus genus, which includes Equine rhinitis B virus; Hepatovirus genus, which includes Hepatîtis A virus; Kobuvirus genus, which includes Aichivirus A, Aichivirus B and Aichivirus C; Megrivirus genus, which includes Melegrivirus A, Human parechovirus; Ljungan virus; Piscevirus genus, which includes Fathead minnow picomavirus; Salivirus genus, which includes Salivirus A; Sapelovirus genus, which includes porcine sapelovirus, simian sapelovirus and avian sapelovirus; Senecavîrus genus, which includes Seneca Valley virus; Teschovirus genus, which includes Porcine teschovirus; Tremovirus genus, which includes avian encephalomyelitis virus. Diseases associated with the Picomaviridae family include: paralysis (non-polio and polio-type), summer cold, meningitis, dîanrhea caused by Enteroviruses; foot-and-mouth disease (bovine) caused by Aphthoviruses; myocarditis caused by Cardioviruses; common cold caused by Rhinoviruses; and hepatîtis caused by Hepatoviruses. Diseases associated with the Picomaviridae family include: paralysis (nonpolio and polio-type), summer cold, meningitis, diarrhea caused by Enteroviruses; foot-andmouth disease (bovine) caused by Aphthoviruses; myocarditis caused by Cardioviruses; common cold caused by Rhinoviruses; and hepatîtis caused by Hepatoviruses.
Enterovirus genus
The Enterovirus genus includes the following twelve species: Enterovirus A, Enterovirus B, Enterovirus C, Enterovirus D, Enterovirus E, Enterovirus F, Enterovirus G, Enterovirus H, Enterovirus J, Rhinovirus A, Rhinovirus B, Rhînovirus C. Within these twelve species are the serotypes: l ) Coxsackievirus: a) serotypes CV-A2, CV-A3, CV-A4, CV-A5, CV-A6, CV-A7, CV-A8, CV-AIO, CV-A12, CV-A14 & CV-A16 found under the species Enterovirus A; b) serotypes CV-Bl, CV-B2, CV-B3, CV-B4, CV-B5, CV-B6 & CV-A9 found under the species; Enterovirus B; c) serotypes CV-Al, CV-Al l, CV-A13, CV-A17, CV-A19, CV-A20, CV-A21, CV-A22 & CV-A24 found under the species Enterovirus C; 2) Echovirus serotypes
-918883
E-I, E-2, E-3, E-4, E-5, E-6, E-7, E-9, E-l l, E-12, E-13, E-14, E-I5, E-16, E-17, E-18, E-19, E-20, E-2l, E-24, E-25, E-26, E-27, E-29, E-30, E-3l, E-32, & E-33 found under the species Enterovirus B; 3) Enterovirus a) types EV-A71, EV-A76, EV-A89, EV-A90, EV-A91, EVA92, EV-Al 14, EV-Al 19, SV19, SV43, SV46 & BAI3 found under the species Enterovirus
A; b) types EV-B69, EV-B73, EV-B74, EV-B75, EV-B77, EV-B78, EV-B79, EV-B80, EVB8l, EV-B82, EV-B83, EV-B84, EV-B85, EV-B86, EV-B87, EV-B88, EV-B93, EV-B97, EV-B98, EV-BIOO, EV-BlOl, EV-B106, EV-B107, EV-BHO & SA5 found under the species Enterovirus B; c) types EV-C95, EV-C96, EV-C99, EV-C102, EV-C104, EV-Cl 05, EVC109, EV-Cl 16, EV-Cl 17 & EV-Cl 18 found under the species Enterovirus C; d) types EV10 D68, EV-D70, EV-D94, EV-D111 & EV-D120 found under the species Enterovirus D; e) types: EV-H1 found under the species Enterovirus H; f) types: SV6, EV-J103, EV-J108, EVJ112, EV-JI15 and EV-J121 found under the species Enterovirus J; 4) Human rhînovirus a) types HRV-A1, HRV-A2, HRV-A7, HRV-A8, HRV-A9, HRV-A10, HRV-A11, HRV-A12, HRV-A13, HRV-A15, HRV-A16, HRV-A18, HRV-A19, HRV-A20, HRV-A2I, HRV-A22,
HRV-A23, HRV-A24, HRV-A25, HRV-A28, HRV-A29, HRV-A30, HRV-A31, HRV-A32, HRV-A33, HRV-A34, HRV-A36, HRV-A38, HRV-A39, HRV-A40, HRV-A41, HRV-A43, HRV-A44, HRV-A45, HRV-A46, HRV-A47, HRV-A49, HRV-A50, HRV-A51, HRV-A53, HRV-A54, HRV-A55, HRV-A56, HRV-A57, HRV-A58, HRV-A59, HRV-A60, HRV-A61, HRV-A62, HRV-A63, HRV-A64, HRV-A65, HRV-A66, HRV-A67, HRV-A68, HRV-A71,
HRV-A73, HRV-A74, HRV-A75, HRV-A76, HRV-A77, HRV-A78, HRV-A80, HRV-A81,
HRV-A82, HRV-A85, HRV-A88, HRV-A89, HRV-A90, HRV-A94, HRV-A95, HRV-A96, HRV-A98, HRV-A100, HRV-AI01, HRV-A102 & HRV-A103 found under the species Rhinovirus A; b) types HRV-B3, HRV-B4, HRV-B5, HRV-B6, HRV-B14, HRV-B17, HRVB26, HRV-B27, HRV-B35, HRV-B37, HRV-B42, HRV-B48, HRV-B52, HRV-B69, HRV25 B70, HRV-B72, HRV-B79, HRV-B83, HRV-B84, HRV-B86, HRV-B91, HRV-B92, HRVB93, HRV-B97, & HRV-B99 found under the species Rhinovirus B; c) types HRV-C1, HRVC2, HRV-C3, HRV-C4, HRV-C5, HRV-C6, HRV-C7, HRV-C8, HRV-C9, HRV-C10, HRVC11, HRV-C12, HRV-C13, HRV-C14, HRV-C15, HRV-C16, HRV-C17, HRV-C18, HRVC19, HRV-C20, HRV-C21, HRV-C22, HRV-C23, HRV-C24, HRV-C25, HRV-C26, HRV30 C27, HRV-C28, HRV-C29, HRV-C30, HRV-C31, HRV-C32, HRV-C33, HRV-C34, HRV-1018883
C35, HRV-C36, HRV-C37, HRV-C38, HRV-C39, HRV-C40, HRV-C41, HRV-C42, HRVC43, HRV-C44, HRV-C45, HRV-C46, HRV-C47, HRV-C48, HRV-C49, HRV-C50 & HRVC5l found under the species Rhinovirus C; 5) Poliovirus serotypes PV-l, PV-2, & PV-3 found under the species Enterovirus C.
Coxsackie A viruses are maînly associated with human hand, foot and mouth disease. Coxsackie B viruses can cause signs and symptoms, simîlar to a cold, but these viruses also can lead to more serions diseases, including myocarditis (inflammation of the heart); pericarditis (inflammation of the sac lining the heart); meningitis (inflammation of the membranes that line the brain and spinal cord); and pancreatitis (inflammation of the pancréas). Echoviruses are a cause of many of the nonspecific viral infections. It is mainly found in the intestine, and can cause nervous disorders. The usual symptoms of Coxsackie and echovirus are fever, mild rash, and mild upper respiratory tract (URT) illness.
Diseases caused by viruses belonging to the Enterovirus genus include, but not limited to, poliomyelitis; poly-like syndrome; nonspecific febrile illness, which may hâve one or more of the following symptoms: fever, muscle pain, sore throat, gastrointestinal distress/abdominal discomfort, and headache; septic meningitis; Bornholm disease or épidémie pleurodynia, which may be characterized by one or more of the following symptoms: severe paroxysmal pain in the chest and abdomen, fever, nausea, headache, and emesis; pericarditis and/or myocarditis, which may hâve one or more of the following symptoms: fever, dyspnea and chest pain; acute hémorrhagie conjunctivitis; herpangina, which may involve one or more of the following symptoms: vesicular rash in the oral cavity and on the pharynx, high fever, sore throat, malaise, dysphagia, loss of appetite, back pain, and headache; hand, foot and mouth disease.
PARAMYXOVIRIDAE VIRAL FAMILY
The Paramyxoviridae family is a (-)ssRNA viral famîly. Humans, vertebrates, and birds serve as natural hosts for paramyxoviruses. There are currently 36 species in this family, divided among 18 généra. Diseases associated with the Paramyxoviridae family include: measles, mumps, respiratory tract infections. Paramyxoviridae is split into two sub-families, Paramyxovirinae and Pneumovirinae. The généra of the Paramyxoviridae family include:
-H
Aquaparamyxovirus genus, which includes Atlantic salmon paramyxovirus; Avulavirus genus, which includes Avian paramyxoviruses l -12, Goose paramyxovirus and Newcastle disease virus; Ferlavirus genus, which includes Fer-de-Lance paramyxovirus; Henipavirus genus, which includes Hendra virus, Nipah virus and Cedar virus; Morbillivirus genus, which includes canine distemper virus, catecean morbillius virus, measles virus, peste-des-petitsruminants virus, phocine distemper virus, rinderpest virus; Respirovirus genus, which includes Sendai virus, human parainfluenza virus type l and human parainfluenza virus type 3; Rubulavirus genus, which includes mumps virus, human parainfluenza virus type 2 and human parainfluenza virus type 4; Tupaia paramyxovirus (TPMV)-like viruses; Metapneumovirus genus, which includes avian metapneumovirus and human metapneumovirus; pneumovirus genus, which includes human respiratory syncytial virus (HRSV), bovine respiratory syncytial virus, ovine respiratory syncytial virus, caprine respiratory syncytial virus, pneumonia virus of mice,
Henipaviruses, such as Hendra virus, Nipah virus and Cedar virus can cause an illness or even death in domestic animais, including equines, felines, pigs, as well as in humans.
The Paramyxoviridae family includes Human parainfluenza viruses (HPIV) types l-4. HPIVl may be a cause of croup, also known as laryngotracheobronchitis, which is a type of respiratory infection. The infection may lead to swelling inside the trachea, which interfères with normal breathing and produces the classic symptoms of barking cough, stridor, and a hoarse voice. Fever and runny nose may also be présent. HPIV-2 may also be a cause of croup as a cause of other upper and lower respiratory tract illnesses. HPIV-3 may be a cause of with bronchiolitis and pneumonia. HPIV-3 may principally target young children, such as those aged <l year. Bronchiolitis is inflammation of the bronchioles, the smallest air passages of the lungs. It présents with coughing, wheezing and/or shortness of breath which can cause some children difficulty in feeding. Pneumonia is an inflammatory condition of the lung affecting primarily the microscopie air sacs known as alveoli. Typical signs and symptoms include a varying severity and combination of productive or dry cough, chest pain, fever, and trouble breathing, depending on the underlying cause.
Sendai virus (SeV), also known as murine parainfluenza virus type l or hemagglutinating virus of Japan (HVJ) is responsible for a highly transmissible respiratory tract infection in -1218883 mice, hamsters, guinea pigs, rats, and occasionally pigs. Symptoms of the Sendai virus caused infection include sneezing, hunched posture, respiratory dîstress, porphyrin discharge form eyes and/or nose, lethargy, failure to thrive in surviving babies and young rats, anorexia. Viruses belonging to the genus Pneumovirus, such as human respiratory syncytial virus, may cause a number of diseases involved with respiratory illness, which may range from a lesssevere upper-respiratory illness to severe bronchiolitis or pneumonia. Symptoms of such diseases may include mild symptoms such as rhinitis, coughing, and decreased appetite and more serions symptoms, such as wheezing, difficulty breathing, fever, bronchiolitis and pneumonia.
In some embodiments, a thiazolide compound, such as nitazoxanide and/or tizoxanide, may reduce a duration of symptoms caused by or associated with human respiratory syncytial virus. For example, a thiazolide compound, such as nitazoxanide and/or tizoxanide, may reduce a duration of symptoms caused by or associated with human respiratory syncytial virus by at least 12 hours or at least 24 hours or at least 36 hours or at least 48 hours or at least 60 hours or at least 72 hours or at least 84 hours or at least 96 hours or at least 108 hours or at least 120 hours or at least 132 hours or at least 144 hours. For examples, in some embodiments, a duration of symptoms caused by or associated with human respiratory syncytial virus may be reduced by from 12 hours to 144 hours or from 24 hours to 132 hours or from 36 hours to 120 hours or from 48 hours to 108 hours or from 60 hours to 96 hours or from 66 hours to 90 hours from 72 hours to 84 hours or any subrange or value within these ranges.
In some embodiments, the thiazolide compound may be nitazoxanide (l, see formula below) or a pharmaceuticaily acceptable sait thereof. Nitazoxanide is a licensed product in the United States for the treatment of infectious gastroenteritis. In some embodiments, the thiazolide compound may be tizoxanide or its pharmaceuticaily acceptable sait, also shown below.
-1318883
Ο
RM-4848
Ο
RM-5038
In some embodiments, nitazoxanide and tizoxanide may be used together as a combination.
In some embodiments, the thiazolide compound may be RM-4848, which is a substituted thiazolide having the same structure as tizoxanide, but including a chloro group substituted for the nitro group, thus resulting in the compound N-(5-chlorothiazol-2-yl)-2hydroxybenzamîde. In some embodiments, the thiazolide compound may be RM-5038, which is an ester prodrug of RM-4848. RM-4848 and RM-5038 are disclosed for example, in U.S. patent application publication no. 20120294831.
-1418883
Thiazolide compounds may be synthesized, for example, according to published procedures U.S. patents nos. 3,950,35! and 6,020,353, PCT W02006042195A! and US2009/0036467A. Other suitable thiazolide compounds are disclosed in U.S. Pat. Nos. 7,645,783, 7,550,493, 7,285,567, 6,117,894, 6,020,353, 5,968,961, 5,965,590, 5,935,591, and 5,886,013.
In some embodiments, when used against a virus belonging to the Paramyxoviridae family, the thiazolide compound, such as nitazoxanide and/or tizoxanide, or RM-4848 and its ester (such as RM5O38), may reduce an intracellular level of the mature F-protein of the virus. For example, when used against a virus belonging to the Respirovirus genus, such as Sendai virus, the thiazolide compound may reduce an intracellular level of such viral protein. When used against a virus belonging to the Pneumovirus genus, such as respiratory syncytial virus, the thiazolide compound may reduce an intracellular level of such viral protein. When used against a virus belonging to the Henipavirus genus, such as Hendra virus, the thiazolide compound may reduce an intracellular level of such viral protein.
In some embodiments, when used against a virus belonging to the Picornaviridae family, such as a virus belonging to the Enterovirus genus, the thiazolide compound, such as nitazoxanide and/or tizoxanide, may be administered together with a direct-acting antiviral agent that inhibits réplication of viruses belonging to the Picornaviridae family.
Direct-acting antiviral agents include, but are not limîted to, 3C protease inhibitors, such as rupintrivir, Pyrazoles 17 and 18, and nucleoside analog inhibitors, such as MK-0608.
Preferably, a direct-acting antiviral agent is administered in an effective amount, which is an amount necessary to achieve a desired effect when the direct-acting antiviral agent is used together with a thiazolide compound, such as nitazoxanide and/or tizoxanide.
A thiazolide compound, such as nitazoxanide and/tizoxanide, may be administered concurrently or subsequently with a neuraminidase inhibitor.
When a virus belongs to the Enterovirus genus, administering of a thiazolide compound, such as nitazoxanide and/or tizoxanide, alone or together with a direct-acting antiviral agent may alleviate at least one symptom of a disease or condition caused by or associated with such virus, which symptom may be, for example, fever, cough, sore throat, nasal obstruction, fatigue, headache, myalgia, and/or feverishness. For example, in some embodiments, when a
-1518883 virus belongs to the Enterovirus genus, administering of a thiazolide compound, such as nitazoxanide and/or tizoxanide, alone or together with a direct-acting antiviral agent may a) reduce fever caused by or associated with a disease or condition caused by or associated with such virus and b) alleviate at least one symptom of the disease or condition, which symptom may be, for example, cough, sore throat, nasal obstruction, fatigue, headache, myalgia, and/or feverishness. In some embodiments, wherein administering of a thiazolide compound, such as nitazoxanide and/or tizoxanide, alone or together with a neuraminidase inhibitor, such as oseltamivir, may a) reduce the fever caused by or associated with the disease or condition, and b) alleviate at least one respiratory symptom caused by or associated with the disease or condition and at least one constitutional symptom associated with the disease or condition, wherein the at least one respiratory symptom is selected from cough, sore throat, and/or nasal obstruction and wherein the at least constitutional symptom is selected from fatigue, headache, myalgia, and feverishness.
The tenn “sait” may be used in its broadest sense. For example, the term “sait” includes hydrogen salts and hydroxide salts with ions of the présent compound. In some embodiments, the term sait may be a subclass referred to as pharmaceutically acceptable salts, which are salts of the présent compounds having a pharmacological activity and which are neither biologically nor otherwise undesirable. In ail embodiments, the salts can be formed with acids, such as, without limitation, hydrogen, halides, acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycero-phosphate, hemisulfate, heptanoate, hexanoate, hydrochloride hydrobromîde, hydroiodide, 2-hydroxyethane sulfonate, lactate, maleate, methanesulfonate, 2naphthalenesulfonate, nîcotinate, oxalate, thiocyanate, tosylate, and undecanoate. In ail embodiments, the salts can be formed with bases, such as, without limitation, hydroxide, ammonium salts, alkali métal salts such as lithium, sodium and potassium salts, alkaline earth métal salts such as calcium, magnésium salts, aluminum salts, salts with organic bases such as ammonia, methylamine, diethylamine, ethanolamine, dicyclohexylamine, Nmethylmorpholine, N-methyl-D-glucamine, and salts with amîno acids such as arginine and lysine. Basic nitrogen-containing groups can be quartemized with agents including lower
-1618883 alkyl halides such as methyl, ethyl, propyl and butyl chlorides, bromides and iodides; dialkyl sulfates such as dimethyl, diethyl, dibutyl and diamyl sulfates; long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides; and aralkyl halides such as benzyl and phenethyl bromides.
The terms “therapeutically acceptable sait,” and “pharmaceutically acceptable sait,” as used herein, represent both salts and zwitterionic forms of the compounds of the present invention which are water or oil-soluble or dispersible; which are suitable for treatment of diseases without undue toxicity, irritation, and allergie response; which are commensurate with a reasonable benefit/risk ratio; and which are effective for their intended use. The salts can be io prepared during the final isolation and purification of the compounds or separately by reacting the appropriate compound in the form of the free base with a suitable acid. Représentative acid addition salts include acetate, adipate, alginate, L-ascorbate, aspartate, benzoate, benzene sulfonate (besylate), bisulfate, butyrate, camphorate, camphorsulfonate, citrate, digluconate, formate, fumarate, gentisate, glutarate, glycérophosphate, glycolate, hemisulfate, heptanoate, 15 hexanoate, hippurate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethane sulfonate (isethionate), lactate, maleate, malonate, DL-mandelate, mesitylenesulfonate, methanesulfonate, naphthylenesulfonate, nicotinate, 2-naphthalenesuIfonate, oxalate, pamoate, pectinate, persulfate, 3-phenylproprionate, phosphonate, picrate, pivalate, propionate, pyroglutamate, succinate, sulfonate, tartrate, L-tartrate, trichloroacetate, trifluoroacetate, phosphate, glutamate, bicarbonate, para-toluenesulfonate (p-tosylate), and undecanoate. Also, basic groups in the compounds of the present invention can be quatemized with methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides; dimethyl, diethyl, dibutyl, and diamyl sulfates; decyl, lauryl, myristyl, and steryl chlorides, bromides, and iodides; and benzyl and phenethyl bromides. Examples of acids which can be employed to form therapeutically acceptable addition salts include inorganic acids such as hydrochloric, hydrobromic, sulfuric, and phosphoric, and organic acids such as oxalic, maleic, succinic, and citric. Salts can also be formed by coordination of the compounds with an alkali métal or alkaline earth ion. Hence, the present invention contemplâtes sodium, potassium, magnésium, and calcium salts of the compounds of the compounds of the present invention and the like.
-1718883
Basic addition salts can be prepared during the final isolation and purification of the compounds by reacting a carboxyl, phénol or similar group with a suitable base such as a métal hydroxide, carbonate, or bicarbonate, or with ammonia or an organic primary, secondary, or tertiary amine. The cations of therapeutically acceptable salts include lithium, sodium, potassium, calcium, magnésium, and aluminum, as well as nontoxic quatemary amine cations such as ammonium, tétraméthylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, diethylamine, ethylamine, tributylamîne, pyridine, Ν,Ν-dimethylaniline, N-methylpiperidine, N-methylmorpholine, dicyclohexylamine, procaine, dibenzylamine, Ν,Ν-dibenzylphenethylamine, l-ephenamine, and Ν,Ν'-dibenzylethylenediamine. Other représentative organic amines useful for the formation of base addition salts include ethylenediamine, ethanolamine, di éthanol amine, piperidine, and piperazine.
In some embodiments, the thiazolide compound may be administered as a part of a pharmaceutical composition. The pharmaceutical composition may include in addition to the thiazolide compound may include a carrier, such as a pharmaceutically acceptable carrier. The term “carrier” may be used in its broadest sense. For example, the tenu “carrier refers to any carriers, diluents, excipients, wetting agents, buffering agents, suspending agents, lubricating agents, adjuvants, vehicles, delivery Systems, emulsifiers, disintegrants, absorbents, preservatives, surfactants, colorants, flavorants, and sweeteners. In some embodiments, the carrier may be a pharmaceutically acceptable carrier, a term narrower than carrier, because the term pharmaceutically acceptable carrier means a non-toxic that would be suitable for use in a pharmaceutical composition. Actual dosage levels of active ingrédients in the pharmaceutical compositions may vary so as to administer an amount of the active compound(s) that is effective to achieve the desired therapeutic response for a particular patient.
The selected dose level may dépend on the activity of the thiazolide compound, the route of administration, the severity of the condition being treated, and the condition and prior medical history of the patient being treated. However, it is within the skill of the art to start doses of the compound(s) at levels lower than required to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved. If desired, the effective
-1818883 daily dose may be divided into multiple doses for purposes of administration, for example, two to four doses per day. It will be understood, however, that the spécifie dose level for any particular patient may dépend on a variety of factors, including the body weight, general health, diet, time and route of administration and combination with other therapeutic agents and the severity of the condition or disease being treated.
The pharmaceutical compositions may be administered systemically, for example, in an oral formulation, such as a solid oral formulation. For example, it may be in the physical form of a powder, tablet, capsule, lozenge, gel, solution, suspension, syrup, or the like. In some embodiments, the pharmaceutical composition may be in a form of a formulation disclosed in U.S. patents nos. 8,524,278 and 9,351,937. Such formulation may, for example, include a controlled release portion, which includes a thiazolide compound, such as nitazoxanide and/or tizoxanide; and an immédiate release portion, which contains a thiazolide compound, such as nitazoxanide and/or tizoxanide. These compositions may be administered in a single dose or in multiple doses which are administered at different times.
In some embodiments, the total amount of a thiazolide compound, such as nitazoxanide and/or tizoxanide, in the composition may be about 60% to 75% by weight of the composition. The composition may be formulated for immédiate release, controlled release or sustained release. The compositions may contain one or more additional pharmaceutically acceptable additives or excipients. These excipients are therapeutically inert ingrédients that are well known and appreciated in the art. As used herein, the terrn inert ingrédient may refer to those therapeutically inert ingrédients that are well known in the art of pharmaceutical manufacturing, which can be used singly or in various combinations, and include, for example, diluents, disintegrants, binders, suspending agents, glidants, lubricants, fiilers, coating agents, solubilizîng agent, sweetening agents, coloring agents, flavoring agents, and antioxidants. See, for example, Remington: The Science and Practice ofPharmacy 1995, edited by E. W. Martin, Mack Publishing Company, 19th édition, Easton, Pa.
Examples of diluents or fiilers include, but are not limited to, starch, lactose, xylitol, sorbitol, confectioner's sugar, compressible sugar, dextrates, dextrin, dextrose, fructose, lactitol, mannitol, sucrose, talc, microcrystalline cellulose, calcium carbonate, calcium phosphate dibasic or tribasic, dicalcium phosphaste dehydrate, calcium sulfate, and the like. The amount -1918883 of diluents or fillers may be in a range between about 2% to about 15% by weight of the entire composition.
Examples of disîntegrants include, but are not limited to, alginic acid, methacrylic acid DVB, cross-lînked PVP, microcrystalline cellulose, sodium croscarmellose, crospovidone, polacriiin potassium, sodium starch glycolate, starch, including com or maize starch, pregelatinized starch and the like. Disintegrant(s) typîcally represent about 2% to about 15% by weight of the entire composition.
Examples of binders include, but are not limited to, starches such as potato starch, wheat starch, com starch; microcrystalline cellulose; celluloses such as hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropylmethyl cellulose (HPMC), ethyl cellulose, sodium carboxy methyl cellulose; natural gums like acacia, alginic acid, guar gum; liquid glucose, dextrin, povidone, syrup, polyethylene oxide, polyvinyl pyrrolidone, poly-N-vinyl amide, polyethylene glycol, gelatin, poly propylene glycol, tragacanth, and the like. The amount of binder(s) is about 0.2% to about 14% by weight of the entire composition.
Examples of glidants include, but are not limited to, Silicon dioxîde, colloïdal anhydrous silica, magnésium trisilicate, tribasic calcium phosphate, calcium silicate, magnésium silicate, colloïdal Silicon dioxide, powdered cellulose, starch, talc, and the like. The amount of glidant(s) is about 0.01% to about 0.3% by weight of the entire composition.
Examples of lubricants include, but are not limited to, magnésium stéarate, aluminum stéarate, calcium stéarate, zinc stéarate, stearic acid, polyethylene glycol, glyceryl behenate, minerai oil, sodium stearyl fùmarate, talc, hydrogenated vegetable oil and the like. The amount of lubricant(s) is about 0.2% to about 1.0% by weight of the entire composition.
The compositions may contain a binder that is a low-viscosity polymer. Examples of lowviscosity polymers include, but are not limited to, low-viscosity hydroxypropyl methylcellulose polymers such as those sold by Dow Chemical under the tradename MethoceL™ (e.g., Methocel E50LV™, Methocel K.100LVR™, and Methocel F50LVR™) and low-viscosity hydroxyethylcellulose polymers. The low-viscosity polymer is typîcally présent at about 10% to about 20%, or about 10% to about 15%, or preferably about 12%, of the total weight of the entire composition, or, in those embodiments having controlled release
-2018883 and immédiate release portions, the low-viscosity polymer in the controlled release portion is typically présent at about 15% to about 20%, preferably about 18%, of the weight of the controlled release portion.
The compositions may further comprise a coating materiaL The coating material is typically présent as an outer layer on the dosage form that completely covers the formulation. For example, in sonie embodiments, the dosage form is an oral tablet in which the controlled release portion forms a first layer of the tablet and the immédiate release portion forms a second layer that is deposited on top of the first layer to form a core tablet. In such embodiments, e.g., the coating material can be in the form of an outer coating layer that is deposited on top of the core tablet. The coating material typically is about I% to about 5% by weight of the composition, and may comprise hydroxypropylmethylcellulose and/or polyethylene glycol, and one or more excipients selected from the group comprising coating agents, opacifiers, taste-masking agents, fillers, polishing agents, coloring agents, antitacking agents and the like. Examples of film-coating substances and methods for using such coating substances are well known to those of skill in the art.
The composition comprising a thiazolide compound, such as nitazoxanide and/or tizoxanide, may be administered for a length of time suitable to effectively treat a disease or condition caused by or associated with a virus belonging to the Picomaviridae family, such as a virus belonging to the Enterovinis genus, or a virus belonging to the Paramyxoviridae family. A number of appropriate dosages and regimen may be used for the compositions. In some embodiments, administration may be carried out over a period of about 3 days to about 104 weeks. In some embodiments, administration may be carried out over a period longer than 104 weeks and may even be carried out indefinitely. Appropriate regimens may be determined by a physician.
In some embodiments, administering of a thiazolide compound, such as such as nitazoxanide and/or tizoxanide, may start within 24 hours or within 36 hours or within 48 hours or within 60 hours or within 72 hours or within 96 hours from an onset in a patient, such as a human being, of at least one symptom of a disease or condition caused by or associated with a virus belonging to the Picomaviridae family, such as a virus belonging to the Enterovirus genus, or with a virus belonging to the Paramyxoviridae family. For example, for a virus belonging to -2118883 the Enterovirus genus, administering of a thiazolide compound, such as such as nitazoxanide and/or tizoxanide, may start within 24 hours or within 36 hours or within 48 hours or within 60 hours or within 72 hours or within 96 hours from an onset in a patient, such as a human being, of at least one symptom of a disease or condition caused by or associated with such virus, which may be, for example, fever, cough, sore throat, nasal obstruction, fatigue, headache, myalgia, and feverishness.
In some embodiments, a daily dose of a thiazolide compound, such as nitazoxanide and/or tizoxanide, administered to a human may be from 100 mg to 1300 mg or from 200 mg to 1200 mg or from 250 mg to 1100 mg or from 300 mg to 1000 mg or any dose value or subrange within these ranges. Exemplary dosage values include 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 700 mg or 800 mg.
In some embodiments, a thiazolide compound, such as nitazoxanide and/or tizoxanide, may be administered at least for 2 days or at least for 3 days or at least for 4 days or at least for 5 days or at least for 6 days. In some embodiments, a thiazolide compound, such as nitazoxanide and/or tizoxanide, may be administered for a period from 2 to 14 days or from 3 to 10 days or from 4 to 7 days or any value or subrange within these ranges. In certain embodiments, a thiazolide compound, such as nitazoxanide and/or tizoxanide, may be administered for 5 days. The dose of the thiazolide compound, such as nitazoxanide and/or tizoxanide, may be from 300 mg to 900 mg or from 400 mg to 800 mg or from 500 mg to 700 mg or any dose value or subrange within these ranges. Exemplary dosage values include 300 mg, 400 mg, 500 mg, 600 mg, 700 mg or 800 mg. The thiazolide compound, such as nitazoxanide and/or tizoxanide, may be administered once, twice or thrice daily. In certain cases, 600 mg of nitazoxanide and/or tizoxanide may be administered twice daily. The thiazolide compound, such as nitazoxanide and/or tizoxanide, may be co-adminîstered with a direct-acting antiviral agent, against Picomaviridae, such as rupîntrivir or MK.-0608 or a direct-acting antiviral agent against respiratory syncytial virus such as the fusion inhibitor, GS-5806. A dose of the direct-acting antiviral agent may vary. The direct-acting antiviral agent, such as rupîntrivir, MK-0608 or GS-5806, may be co-administered once, twice or thrice daily. In certain cases, 600 mg of nitazoxanide and/or tizoxanide may be administered
-2218883 twice daily together with an effective amount of the direct-acting antiviral administered twice daily.
A thiazolide compound may be administered to a subject affected by a virus belonging to the Pîcomaviridae family, such as a virus belonging to the Enterovirus genus, or a virus belonging to the Paramyxoviridae family. Such subject may be an animal, including a human being.
Preferably, a thiazolide compound, such as nitazoxanide and/or tizoxanide is administered to a subject affected by a virus belonging to the Piconiaviridae family, such as a virus belonging to the Enterovirus genus, or to a subject affected by a virus belonging to the Paramyxoviridae family in an effective amount, which may mean an amount necessary to achieve a desired effect.
Embodiments described herein are further illustrated by, though in no way limited to, the following working examples.
EXAMPLES
The Paramyxoviridae family comprises many important human viral pathogens, including measles, mumps, parainfiuenza, RSV (respiratory syncytial virus), metapneumoviruses and henipaviruses, which cause some of the deadliest emerging zoonoses. The lack of an effective antiviral therapy underscores the need for novel drugs effective against these viruses. It was shown previously that nitazoxanide fNTZ), a safe, orally bioavailable thiazolide licensed in the USA for treating Cryptosporidiumparvum and Giardia lamblia infections, has antiviral activity against influenza viruses. Herein we investigated the activity of NTZ and a class of second-generation thiazolides (SGT), RM-4848 and RM-5038 against Paramyxoviridae infection in vitro, using Sendai virus (SeV) and RSV-A2 as models, and explored the mechanism of the antiviral action. Virus yield was determined by hemagglutinin titration and infectivity assay in monkey and human cells; cell vîability was determined by MTT assay. Viral protein synthesis/maturation was characterized by SDS/PAGE-autoradiography after [35S]methionine-labeling, immunoprécipitation and/or EndoH-digestion, and by immunofluorescence and Westem-blot analysis in infected cells or in cells transiently transfected with FLAG-tagged Hendra virus (HeV) fusion (F) protein.
-2318883
NTZ and SGT showed a remarkable antiviral activity against SeV, reducing virus yield dosedependently with SI ranging from >50 to >625 depending on the m.o.i., and protecting host cells from virus-induced damage. Thiazolides did not affect virus entry nor caused a general inhibition of viral protein synthesis whereas they inhibited the maturation and intracellular translocation of the viral HN and F glycoproteins. In particular, NTZ also caused a decrease in intracellular ievels of the F protein, which plays a critical rôle in cell fusion and infectivity of the virion. This effect was not due to protein dégradation via the ubiquitin-proteasome System or autophagy, since it could not be rescued by treatment with the protéasome inhibitor bortezomib or autophagy inhibitor chloroquine. Instead SeV F protein was found to be present in an insoluble State in NTZ-treated cells, suggesting that a drug-induced defect in maturation would lead to F protein aggregation. Interestingly, thiazolides similarly affected Hendra virus F protein in cells transiently expressing FLAG-tagged HeV -F in the absence of viral infection, suggesting a cell-mediated mechanism. The results indicate that NTZ is effective against Paramyxovirus infection, acting at post-entry level by a novel mechanism targeting viral glycoproteins. NTZ treatment was also effective against RSV, suggesting a general effect of the drug on Paramyxoviridae family members. Results of the study presented in Figures 4-19.
MATERIALS and METHODS
Cell Culture, Treatment and Transfections. Human A549 alveolar type Il-like épithélial cells and cervical carcinoma HeLa cells, and African green monkey kidney cells (AGMK, 37RC cell line) were grown at 37°C in a 5% CO2 atmosphère in RPMl medium (Gibco-Invitrogen, Carlsbad, CA) (AGMK, A549), or DMEM medium (Gibco-Invitrogen, Carlsbad, CA) (HeLa), supplemented with 10% fêtai calf sérum (FCS), 2 mM glutamine and antibiotics. Nitazoxanide (NTZ), tizoxanide (TIZ) (Romark Laboratories, L.C.), glycosylation inhibitor tunicamycin (TM), protéasome inhibitor bortezomib and autophagy inhibitor chloroquine, (Sigma-Aldrich, St. Louis, MO) dissolved in DMSO stock solution (25 mg/ml) were diluted in culture medium and added to infected cells immediately after a one-hour adsorption period, unless differently specified. Compounds were maintained in the medium for the duration of the experiment. Controls received equal amounts of DMSO vehicle, which did not affect cell vîability or virus réplication. Each concentration of each compound was tested in duplicate
-2418883 and each experiment was repeated at least twice. For transfection experiments, semiconfluent monolayers of HeLa cells were transiently transfected with a pCMV-driven construct containing the gene expressing the F protein of human respiratory syncytial virus (RSV, subtype A, strain A2) linked to a FLAG-tag (RSV-F ORF C-Flag tag, Sino Biological Inc.), a pCMV-driven construct containing the gene expressing the F protein of Hendra virus (HeV) linked to a FLAG-tag (HeV-F ORF C-Flag tag, Sino Biological Inc.), or the pcDNA3 vector as control. Transfections were performed using jetPRIME Transfection Reagent (Polyplus transfection), according to the manu facturer’s instructions.
Cytotoxicity. Cell viabiiity was determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide (MTT) to MTT formazan conversion assay (Sigma-Aldrich, St Louis, MO). For MTT assay, reduced MTT (formazan) was extracted from cells by adding 100 ml of acidic isopropanol containing 10% Triton X-100, and formazan absorbance was measured in an ELISA microplate reader at two different wavelengths (540 and 690 nm). The 50% léthal dose (LD50) was calculated using Prism 5.0 software (Graph-Pad Software Inc., San Diego, CA). Microscopical examination of mock-infected or virus-înfected cells was performed daily to detect virus-induced cytopathic effect and possible morphological changes and/or cytoprotection induced by the drug. Microscopy studies were performed using a Leica DM-IL microscope and images were captured on a Leica DC 300 caméra using Leica ImageManager500 software.
Virus Préparation, Infection and Titration. Sendai virus (SeV) was grown in the allantoic cavity of I0-day-old embryonated eggs. After 48 h at 37°C, the allantoic fluid was harvested and centrifuged at 5,000 rpm for 30 minutes to remove cellular débris, and virus titers were determined by hemagglutinin (HA) titration and plaque assay, according to standard procedures (Bemasconi et al., 2005, Pica et al., 2000).
For virus infection, confluent AGMK cell monolayers were infected with SeV for l hour at 37° C at a multiplicity of infection (MOI) of 3 PFU (Plaque Forming Unît)/cell, unless differently specified. Similar conditions were utilized for infection of human A549 cells. After the adsorption period, the viral inoculum was removed, and cell monolayers were washed three times with phosphate-buffered saline (PBS). The cells were maintained at 37° C în RPMI 1640 culture medium containing 2% fêtai calf sérum. For multistep virus growth -2518883 curves, confluent AGMK/A549 cell monolayers were infected with SeV for l h at 37 °C at an MOI of 0.01 PFU/celi. After the i h adsorption period, the viral inoculum was removed, and cell monolayers were washed three times with PBS. Cells were maintained at 37 °C in RPMI 1640 culture medium containing 0.5% bovine sérum albumin (BSA) and L-l-tosylamide-2phenylethyl chloromethyl ketone (TPCK)-treated trypsin (l pg/ml) (Sigma-Aldrich). Virus yield was determined 24 and 48 h post infection (p.i.) by HA titration or by plaque assay, as previously described (Rossignol et al., 2009). For the plaque assay, serial I0-fold dilutions of the virus were prepared and inoculated on confluent AGMK cell monolayers in 35-mm plates (Corning, New York, NY). After l h at 37 °C, the inoculum was removed and the cells were washed three times with PBS before the addition of RPMI containing 0.5% BSA, l pg/ml TPCK-treated trypsin, and 0.5% SeaPlaque agarose (Lonza). After 72 h at 37 °C, the overlay was removed and cells were fixed with 4% paraformaldéhyde in PBS and stained with l% crystal violet (Sigma-Aldrich). The IC50 (50% inhibitory concentration) and IC90 (90% inhibitory concentration) of the antiviral compounds was calculated using Prism 5.0 software.
Human pneumovirus RSV-A2 (respiratory syncytial virus, A2 strain) was provided by Dr. G. Toms, University of Newcastle, Newcastle upon Tyne, UK. For RSV infection, confluent HeLa cell monolayers were infected for l h at 37°C with RSV-A2 at an MOI of l TCIDs0 (50% tissue culture infectîve dose)/cell. RSV-A2 yield was evaluated by counting the number of virus-induced syncytia at 48 hours p.i., as determined by immunofluorescence (IF) analysis after labeling with a monoclonal antibody spécifie for the fusion protein (F protein) of RSV (anti-F 1E3 antibody, Viratom Ltd., Newcastle upon Tyne, UK). For IF analysis, uninfected and RSV-infected HeLa cell monolayers were fixed with 4% paraformaldheyde (4% in PBS) for 30 min at room température. Fixed cells were incubated with the anti-F 1E3 antibody for l h at room température. Unbound antibody was removed by rinsing in PBS, followed by incubation with FITC-conjugated antimouse antibody for l h at room température. After staining, cells were examined in a Leica DM-il fluorescence microscope equipped with UV excitation filters. The images were captured with a Leica DC-300 caméra using Leica ImageManager500 software. At least 150 syncytia were counted for each samples. Nitazoxanide was found to possess antiviral activity against RSV-A2 at non cytotoxic doses, with an IC50 of 0.3 pg/ml and an IC90 of 0.8 pg/ml.
-2618883
Metabolic Labeling, Analysis of Protein Synthesis and Western Blot. Mock-infected or virusinfected cells were labeled with 10 pCi/ml of [35S]-methionine-cysteine ([35S]-Met/Cys, Redîvue Pro-Mix 35S in vitro cell-labeling mix; GE Healthcare) for the indicated times after 30 minutes starvation in methionine/cysteine-free medium. [35S]-Met/Cys incorporation was determined after cell lysis in RIPA (radîoîmmune précipitation assay) buffer ( 150 mM NaCI, 10 mM Tris-HCl pH 7.5, 4 mM EDTA, l% Triton X-lOO, 600 mM K.C1), containing l mM phenylmethylsulphonyl fluoride (PMSF) and a protease inhibîtor mixture (PIC; Roche Applied Science, Penzberg, Germany). Samples containing the same amount of radioactivity or the same amount of protein were separated by SDS/PAGE (3% stacking gel, 10% resolving gel) and processed for autoradiography, as described (Pica et al., 2000). Autoradiographîc patterns were visualized and quantified in Typhoon-8600 Imager [(Molecular Dynamics Phosphor-Imager™ (MDP)], and images were acquired using ImageQuant software (Amersham Pharmacia Biotech) (MDP analysis).
For analysis of soluble/insoluble proteins whole-cell extracts (WCE) were prepared after lysis in high-salt extraction buffer (Buffer B) (50 mM Tris-HCl pH 7.5, 400 mM NaCI, l mM EDTA, l mM EGTA, l% Triton X-100, 0.5% NP-40 and 10% glycerol) supplemented with 2 mM dithiothreitol (DTT), 20 mM β-glycerolphosphate, I9 mM (p-Nitrophenyl Phosphate) PNPP, 2 mM NajVO4, l mM PMSF and protease-inhibitors cocktail (Roche) (Rossi et al., 2000). Briefly, cells were washed twice with ice-cold PBS and then lysed in Buffer-B (80 μΐ). After one cycle of freeze and thaw, and centrifugation at 15,000 rpm ( 15 min at 4°C), supematant (soluble) and pellet (insoluble) fractions were collected. Insoluble fractions were solubilized in 60 μΐ of Buffer-S (50 mM Tris-HCl pH 8.5, 1% SDS and protease inhibitors) by sonication on ice, using an ultrasonic UP50H processor (Hielscher) (40% amplitude, puise mode: 6x10 sec, 15 sec pauses). Total extracts were obtained by lysing cells in Laemmli Buffer followed by DNA shearing through a 28 %-gauge insulin syringe 10 times.
For Western blot analysis, cell extracts (25 pg) were separated by SDS-PAGE and blotted to nitrocellulose, and fïlters were incubated with the following antibodies: monoclonal anti-SeVF (aF-y236; ID Pharma) and anti-a-tubulin (B-5-1-2, Sigma-Aldrich) antibodies; polyclonal anti-a-tubulin (11H10; Cell Signaling Technology Inc.), anti-FLAG (DYKDDDDK. Tag, Cell
-2718883
Signaling Technology, Inc.) and anti-P-actin (Sigma-Aldrich) antibodies, followed by décoration with peroxidase-labeled anti-rabbit IgG, anti-goat IgG or anti-mouse IgG (SuperSignal détection kit; Pierce).
Immunofluorescence Microscopy. SeV-infected AGMK or A549 cells and RSV-F- or HeVF- transfected HeLa cells grown on coverslips were fixed with 4% paraformaldéhyde in PBS for 20 minutes at room température at 24 h p.i.. Mock-infected or mock-transfected cells were processed similarly. Fixed cells were either incubated with anti-F monoclonal antibodies (aFγ236; ID Pharma) or anti-FLAG (DYKDDDDK Tag, Cell Signaling Technology, Inc.) polyclonal antibodies for l h at 37°C for plasma membrane staining, or were permeabilized with 0. l% TritonX-lOO-PBS for 10 minutes at room température and then incubated with monoclonal anti-F and anti-calnexin (Stressgene) or polyclonal anti-a-tubulin (l IHIO; Cell Signaling Technology Inc.) antibodies for l h at 37°C, followed by décoration with Alexa Fluor488-conjugated (Molecular Probes-Invitrogen) or rhodamine-conjugated (Pierce) goat anti-mouse IgG, and rhodamine-conjugated goat anti-rabbit IgG (Pierce). The nuclei were stained with 4’,6-diamidino-2-phenylindoIe (DAPI) or Hoechst 33342 (Molecular Probes, Invitrogen). The images were captured with an Olympus Fluoview FV-1000 confocal laser scanning System, using FluoVîew-1000 software.
Statistical Analysis. Statistical analysis was performed using Student’s t test for unpaired data. The data are expressed as the means ± S.D. of duplicate samples. p values of <0.05 were considered significant.
References
Bemasconi, D., Amici, C., La Frazia, S., lanaro, A., and Santoro, M. G. (2005) J. Biol. Chem. 280, 24127-24134.
La Frazia, S., Amici, C., and Santoro, M. G. (2006) Antivir. Ther. 11, 995-1004.
Pica, F., Palamara, A. T., Rossi, A., De Marco, A., Amici, C., and Santoro, M. G. (2000) Antimicrob. Agents Chemother. 44, 200-204.
Rossi, A., Kapahi, P., Natoli, G., Takahashi, T., Chen, Y., Karin, M., and Santoro, M. G. (2000) Nature 403, 103-108.
-2818883
Rossignol, J. F,, La Frazia, S., Chiappa, L., Ciucci, A., Santoro, M.G. (2009) J. Biol.Chem. 284, 29798-29808.
Study RM08-3002 (clinical trial data for enterovirus/rhinovirus)
A randomized trial conducted in the United States, Canada, Belgium, Australia and New Zealand studied the effect of NTZ, oseltamivir (OST), NTZ+OST and placebo on time to alleviation of symptoms in subjects 13 to 65 years of âge with uncomplicated influenza or influenza-like illness. 1,941 subjects with fever, at least one moderate or severe respiratory symptom (cough, sore throat, nasal obstruction), and at least one moderate or severe constitutional symptom (feverishness, headache, myalgia, fatigue, cough, nasal obstruction and sore throat) were enrolled within 48 hours of symptom onset. Nasopharyngeal swabs were collected at baseline and subjected to viral culture and RT-PCR to identify viral causes of illness.
After enrollment, patients were randomly assigned to receive treatment with nitazoxanide extended release tablets (NTZ), oseltamivir capsules (OST), NTZ + OST, or placebo. Each treatment was administered twice daily for 5 days. The NTZ dose was 600 mg, and the OST dose was 75 mg.
Patients recorded the severity of their symptoms twice daily for at least 14 days as either absent, mild, moderate or severe, and symptoms were considered alleviated when ail symptoms were graded as absent or mild and remained so for at least 24 hours without the use of symptom relief médications. The primary endpoint of the study was time from first dose to the alleviation of symptoms.
Based upon RT-PCR assays (Lumînex NxTAG Respiratory Pathogen Panel) of nasopharyngeal swab samples, 251 subjects had viruses from the Enterovirus genus (including enteroviruses and rhinoviruses) identified as their sole cause of illness. The times to symptom alleviation for these patients are plotted in a Kaplan-Meier survival analysis chart presented in Figure 2.
Both treatment groups that received NTZ showed statistically significant (p<0.05) réductions in time to alleviation of symptoms compared to patients receiving placebo. The médian réduction of time to symptom alleviation compared to placebo was approximately 47 hours.
-2918883
When the two groups receiving NTZ were combined and compared to the two groups that did not receive NTZ (OST and placebo), patients receiving NTZ showed signifîcant (p=0.005) réductions in the times to symptom alleviation for patients receiving NTZ compared to those that did not. The results of this comparison are presented in Figure 3.
Based upon RT-PCR assays (Luminex NxTAG Respiratory Pathogen Panel) of nasopharyngeal swab samples, 13 patients had respiratory syncytial virus identified as their sole cause of illness. The times to alleviation of symptoms, such as feverishness, headache, myalgia, fatigue, cough, nasal obstruction and sore throat, for these patients are plotted in a Kaplan-Meier survival analysis chart presented in Figure l.
* * *
Although the foregoing refers to particular preferred embodiments, it will be understood that the present invention is not so limited. It will occur to those of ordinary skill in the art that various modifications may be made to the disclosed embodiments and that such modifications are intended to be within the scope of the present invention.
Ail of the publications, patent applications and patents cited in this spécification are incorporated herein by reference in their entirety.
Claims (24)
- WHAT IS CLAIMED IS:1. Use of a pharmaceutical composition comprising at least one of nitazoxanide or tizoxanide or a pharmaceutically acceptable sait thereof in the manufacture of a médicament for treating a disease or condition caused by or associated with a virus belonging to the Paramyxoviridae family.
- 2. The use of claim 1, wherein the virus is a virus belonging to the Respirovirus genus.
- 3. The use of claim 2, wherein the virus is Sendai virus.
- 4. The use of claim 1, wherein the virus is a virus belonging to the Pneumovirus genus.
- 5. The use of claim 4, wherein the virus is human respiratory syncytial virus.
- 6. The use of claim 4, wherein said médicament is for administration to alleviate at least one symptom of the disease or condition, wherein at least one symptom is selected from rhinitis, coughing, decreased appetite, wheezing, difficulty breathing, fever, bronchiolitis and pneumonia.
- 7. The use of claim 1, wherein the virus is a virus belonging to the Henipavirus genus.
- 8. The use of claim 7, wherein the virus is Rendra virus.
- 9. The use of claim I, wherein the subject is a human.
- 10. Use of a pharmaceutical composition comprising at least one of nitazoxanide or tizoxanide or a pharmaceutically acceptable sait thereof, in the manufacture of a médicament for treating a disease or condition caused by or associated with a virus belonging to the Henipavirus genus.
- 11. The use of claim 10, wherein the virus is Hendra virus.
- 12. The use of claim 10, wherein the composition is in an amount which blocks in the subject the maturation of the fusion (F) protein of the virus.
- 13. The use of claim 10, wherein the subject is a human.-3118883
- 14. Use of a pharmaceutical composition comprising at least one of nitazoxanide or tizoxanide or a pharmaceutically acceptable sait thereof, in the manufacture of a médicament for treating a disease or condition caused by or associated with a virus belonging to the Picomaviridae family.
- 15. The use of claim 14, wherein the virus belongs to the Enterovirus genus.
- 16. The use of claim 15, wherein said médicament is for administration to alleviate at least one symptom of the disease or condition, wherein the at least one symptom is selected from fever, cough, sore throat, nasal obstruction, fatigue, headache, myalgia, and feverishness.
- 17. The use of claim 16, wherein said administration is to a) reduce fever caused by or associated with the disease or condition and b) alleviate at least one symptom ofthe disease or condition, wherein the at least one symptom is selected from cough, sore throat, nasal obstruction, fatigue, headache, myalgia, and feverishness.
- 18. The use of claim 17, wherein the administration îs to a) reduce the fever caused by or associated with the disease or condition, and b) alleviate at least one respiratory symptom caused by or associated with the disease or condition and at least one constitutional symptom associated with the disease or condition, wherein the at least one respiratory symptom is selected from cough, sore throat, and nasal obstruction and wherein the at least constitutional symptom is selected from fatigue, headache, myalgia, and feverishness.
- 19. The use of claim 15, wherein the virus is selected from Enterovirus A-J.
- 20. The use of claim 15, wherein the virus is selected from Rhinovirus A-C.
- 21. The use of claim 14, wherein the médicament is for administration to the subject along with a therapeutîcally effective amount of a direct-acting antiviral agent.
- 22. The use of claim 21, wherein the direct-acting antiviral agent is rupintrivir or MK-0608 or a pharmaceutically acceptable sait thereof.
- 23. The use of claim 15, wherein said médicament is for administration which starts within 48 hours of an onset in the subject of at least one symptom of the disease or-3218883 condition, wherein the at least one symptom is selected from fever, cough, sore throat, nasal obstruction, fatigue, headache, myalgia, and feverishness.
- 24. The use of claim 14, wherein the subject is a human.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62/316463 | 2016-03-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
OA18883A true OA18883A (en) | 2019-09-13 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220125767A1 (en) | Thiazolide compounds for treating viral infections | |
CN112999222B (en) | Treatment for inhibiting replication of single stranded RNA viruses | |
BR112016010576B1 (en) | METHODS OF PREPARATION OF INFLUENZA VIRUS REPLICATION INHIBITORS | |
WO2013131496A1 (en) | Component and method for treating viral disease | |
OA18883A (en) | Thiazolide compounds for treating viral infections | |
US11433080B2 (en) | Antiviral treatment | |
CN105362284B (en) | Application of azithromycin and telithromycin in resisting ebola virus infection | |
KR20210129579A (en) | Pharmaceutical compositions for treating a SARS coronavirus infection disease | |
WO2021207444A1 (en) | Methods of treating severe acute respiratory syndrome | |
KR20210129613A (en) | Pharmaceutical compositions for treating a SARS coronavirus infection disease and medical-use thereof | |
US20230143775A1 (en) | Methods of treating coronavirus infections | |
AU2021253866A1 (en) | Methods of treating SARS-CoV-2 infections |